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A lot of viruses have been shown to use a wide variety of attachment molecules on cell surfaces and 
exploit them as receptors and establish an infection (Rostand and Esko, 1997). Viral entry, spread and 
pathogenesis can be better understood by identification of the cell surface receptor(s) of particular virus 
targets (Shukla and Spear, 2001). Virus entry is a two-step process, with the first step being attachment 
of the virus to a primary receptor, followed by the interaction with a co-receptor that is usually a cell-
specific transmembrane protein (Shukla et al., 1999; Summerford and Samulski, 1998). Understanding 
the interaction between proteins on the surface of virus particles and the cell surface receptors which 
are used by the virus particles to enter cells is essential to understand viral tropism, which further helps 
in creating effective antiviral therapies. 
Several published studies have suggested that a number of viruses use the heparan sulfate (HS) 
component of cell surface heparan sulfate proteoglycans (HSPGs), as an main receptor to attach to cells 
(Liu and Thorp, 2002; Rostand and Esko, 1997; Zhu et al., 2011). HS is a glycosaminoglycan (GAG) 
composed of repeating disaccharides of glucosamine and hexuronic acid, joined in alternating 
sequences by 1,4-glycosidic linkages, which gives these carbohydrate chains the flexibility to bind to 
many different proteins (Li and Vlodavsky, 2009; Lindahl, 1990). There are a lot of HS-binding viruses 
from different families and include herpes simplex virus (HSV) (WuDunn and Spear, 1989), human 
papillomavirus (HPV) (Giroglou et al., 2001), hepatitis B virus (HBV) (Cooper et al., 2005), respiratory 
syncytial virus (RSV) (Hallak et al., 2000), foot-and-mouth disease virus (FMDV) (Jackson et al., 1996) and 
the human immunodeficiency virus type 1 (HIV-1) (Roderiquez et al., 1995).  
For this reason, it was important to analyze which proteins are responsible for the entry of HERV-K 
(HML-2). Therefore, the receptors ASCT1/2 (for syncytin-1) and MFSD2A (for syncytin-2) were 
transfected into HEK293T cells. Infection with various pseudotyped HIV showed that viral entry into the 
cells could not be increased. For this reason, it could be assumed that syncytin receptors are not 
primarily responsible for entry. This was the reason that new receptor candidates had to be used for 
further experiments. Previos work by N. Bnnert and A. Richter compared different gene profiles of 
successfully infected cells with HERV-K and thus identified potential receptors that might be specifically 
involved in the onset of the virus. These receptors were the G protein-coupled receptor 56 and 161, the 
cell surface receptor CD63, the neural cell adhesion molecule L1CAM, the golgi sorting receptor sotilin-1 
and the cell surface protein neuroligin-1. Overexpression of these receptors revealed that the g protein-
coupled receptor 56 must have a crucial role in the onset of HERV-K (HML-2), as it could increase the 
infection rate by 3-fold.  
Abstract 
VIII 
Furthermore, this study investigated the influence of heparan sulfates on the entry of HERV-K into the 
cells. For this, free heparan sulfate was incubated before infection with the cells and pseudotyped HIV. 
It turned out that an increase of the heparan sulfate concentration up to 400µg/ml led to a reduction of 
the infection rate up to 40%. A change in the cell surface profile was achieved by enzymatic digestion 
with heparinase I and III and a chemical reaction with sodium chlorate. While heparinase is responsible 
for the digestion of heparan sulfates, sodium chlorate prevents the sulfation of glycosaminoglycan’s. 
Both experiments showed that with increasing concentration, the infection rate of HERV-K decreased. 
The viral entry after enzymatic digestion was reduced up to 50% and after chemical inactivation of 
sulfation by up to 30%. Another approach to verify HS functionality was the overexpression of a specific 
heparan sulfate. Syndecan-1 is a transmembrane (type I) heparan sulfate proteoglycan and is a member 
of the syndecan family. This protein was amplified in HEK293T and HCT116 cells and infected with 
pseudotyped HIV. However, analysis of the resulting luciferase revealed that this had no effect on the 
rate of infection. In further experiments, syndecan-1 was reduced by means of special shRNAs on the 
cell surface. A short hairpin RNA is an artificial RNA molecule with a tight hairpin turn. The expression of 
shRNA in the cell lines was done by the transfection of specific plasmids and blocks the specific mRNA of 
the examined gen. The reduction of the syndecan-1 level on the cell surface led to a reduction in the 
infection rate of HERV-K down to 30% in HEK293T cells. The entry of the viruses into the cells should be 
measured by means of the formed firefly luciferase. In the luciferase assay, reporter constructs carrying 
a firefly luciferase gene behind a CMV promotor and after this, the sequence which is important to 
produce virus particles. 
Based on these facts, it can be said that various heparan sulfates and GPR56 might play a crucial role in 
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Retroviruses compromise enveloped viruses carrying two homologous RNA single plus strands in the 
virus core. These are not translated directly as other RNA viruses, but rewritten with the help of viral 
reverse transcriptase (RT) into double-stranded DNA and incorporated into the host genome. They 
mainly infect animal and human cells from mammals, birds, reptiles, amphibians to fish. Retroviruses 
are found in all vertebrates and usually have very high host specificity. 
At the beginning of the 19th century, retrovirus-induced disease such as bovine leukemia or pulmonary 
adenomatosis in sheep were known but not their cause (Weiss, 2006). In 1908, Ellermann and Bang 
examined the first oncogenic retrovirus, the avian leukemia virus (ALV) and showed that cell-free filtrate 
can be used to transfer chicken leukemia to other chickens (Ellerman V. and Bang O., 1908). Three years 
later, Rous transferred the Rous sarcoma virus (RSV) to healthy chickens with extracts from chicken 
sarcoma. These then also developed tumors (Rous P., 1911). 54 years later he received the Nobel Prize 
for it. In 1936, another tumor-inducing retrovirus was discovered, the mouse mammary tumor virus 
(MMTV), which has tumors in the mammary gland of mice is related (Bittner JJ., 1936). A key step in the 
history of retroviruses has been the discovery of RNA in RSV particles (Crawford LV. and Cawford EM., 
1961). In 1964, Howard M. Temin presented his provirus hypothesis using the example of RSV, which 
states that RNA integrates tumor viruses into the host genome (Temin HM, 1964; Temin HM, 1963). By 
the discovery of reverse transcriptase by David Baltimore and Howard M. Termin, the RNA tumor 
viruses were ultimately renamed retroviruses in 1974 (Baltimore D., 1975). This discovery rejected an 
accepted dogma of molecular biology. It said that the flow of information in cells always goes from DNA 
to protein via RNA (Coffin JM. et al., 1997).  
In the early 1970s, the first viral proteins were described and in 1978 the long terminal repeats (LTRs) 
were identified (Ju G. and Skalka AM., 1980). The description of the first human T-cell leukemia virus 
type-1 (HTLV-1), was made two years later by Robert C. Gallo (Gallo RC., 2005; Poiesz BJ. et al., 1980). In 
1983, Luc Montagier and Francoise Barré Sinoussi discovered the most prominent human phagocytic 
retroviruses, human immunodeficiency virus type 1 (HIV-1), followed by HIV-2 in 1983 (Barré-Sinoussi F. 
et al., 1983; Clavel F. et al., 1986). HIV-1 induces AIDS (Acquired Immune Deficiency Syndrome) and has 
led to a strong drive for retro virology research in recent decades. In 2008, an estimated 33.4 million 
people worldwide were infected with HIV. Every year about two million people die as a result of the 
infection and about the same number of new infections with HIV occurs in the same period. The 
pathogenic agent HTLV-1 applies as cause of adult T-cell leukemia (ATL), but also of HTLV-1-associated 




leukemia and neurological diseases. However, it should be distinguished that HTLV-1 infected CD4+ and 
HTLV-2 CD8+ lymphocytes (Cereseto et al., 1996; Poiesz BJ. et al., 1980). 
Retroviruses are divided into simple and complex retroviruses. Complex retroviruses are distinguished 
by regulatory genes in the viral genome, which lead to the expression of accessory proteins. The current 
phylogenetic taxonomy of Retroviridae has been established by the International Committee on 
Taxonomy of Viruses (ICTV) consisting of 500 international virologists. A distinction is made between the 
subfamilies Orthoretrovirus (Orthoretrovirinae) and Spumaretrovirus (Spumaretrovirinae). Orthotrophic 
viruses are divided into six genera. These included on the one hand the alpha, gamma and epsilon 
retroviruses with a simple genome and on the other hand the beta and delta retroviruses, as well as the 
lentiviruses with a complex genome (Weiss, 2006). 
 
Figure 1: Phylogenetic pedigree of retroviruses 
The seven genera of the Retroviridae and their representatives. The red star means that there are exogenous as well as 
endogenous representatives (Modified from: (Weiss, 2006).  
 
Before comparisons of phylogenetic relationships were made, retroviruses were distinguished by their 
morphological features in electron microscopy and classified taxonomically. Here one distinguished 
between A-, B-, C- and D-type retroviruses depending on their assembly form and the extracellular, 







1.1.1 Endogenous Retroviruses (ERV) 
Endogenous retroviruses (ERVs) are exogenous retroviruses that infect vertebrate germ cells, are 
integrated into the host genome as provirus and transmitted to the offspring via the germ line according 
to the Mendel´s laws. This path of inheritance is called vertical inheritance. Thus, all somatic cells that 
emerge from infected germ cells carry the provirus (Weiss, 2006). There are dozens to thousands of 
ERVs in the vertebrate genome (Herniou et al., 1998). Over millions of years, these have been subjected 
to mutations, deletions and transpositions that have led to inactive proviruses over time. Nevertheless, 
replication-competent proviruses are capable of releasing functional viral particles, such as mouse 
mammary tumor viruses (Fiebig et al., 2006; Weiss, 2006). Some animal retroviruses thus form both 
exogenous and endogenous forms. In addition to MMTV and MLV in mice, these include ALV in 
chickens, the Jaagsiekte sheep retroviruses in sheep, porcine endogenous retroviruses (PERV) in swine 
and feline leukemia virus in cats (Coffin JM. et al., 1997). The viral particles emerging from the 
endogenous form again infect somatic cells via the exogenous pathway or reinfect already infected cells 
(van Nie et al., 1977; Weiss, 2006). This form of inheritance is called horizontal inheritance (Figure 2a).  
 
Figure 2: Proliferation of endogenous retroviruses 
Endogenous retroviruses have three possibilities of propagation. a) In reinfection the provirus is able to form functional viral 
particles, the other somatic cells or the host cell again can infect (horizontal path). b) Retransposition is the intracellular 
multiplication, which also leads to the integration of new proviruses into the cell genome. c) The complementation in trans 
describes the recombination of viruses. If the provirus is partially defective, these can be replaced by components of other 
retroviruses that have infected the cell (red). PIC: preintegration complex (Modified from: (Bannert and Kurth, 2006). 
 
Some endogenous retroviruses multiply intracellularly only. This process, known as retrotransposition, 




A third propagation process, which is based on recombination, is called complementation in trans and 
occurs in proviruses with partially inactive genes. These are replaced by the expression of active genes 
from other proviruses, which can lead to the formation of functional particles (Figure 2c, (Bannert and 
Kurth, 2006). In late 1960s, the first ERVs were discovered. These were the cancer-causing viruses MLV, 
MMTV and ALV (Weiss, 2006). Today, it is known that the retroviral part in the genome of vertebrates 
accounts for about five to ten percent (Herniou et al., 1998; Smit, 1999). More than 3300 endogenous 
retroviruses are already known for humans and chickens. Comparison of viral highly conserved pol 
sequences (800 to 1100 amino acids) demonstrated a wide distribution of ERVs. In 2007, the first 
endogenous lentivirus in European rabbits was found, which is more than seven million years old and 
has complete lentiviral gag, pol and env domains (Katzourakis et al., 2007). 
1.1.2 Human Endogenous Retroviruses (HERV) 
The human genome consists of 8% retroviral elements with terminal LTRs, 4.7% of which are human 
endogenous retroviruses (HERVs) (Bannert and Kurth, 2004; Beimforde et al., 2008; Lander et al., 2001). 
HERVs were also once exogenous retroviruses that infected human endocrine cells, endogenized and 
multiply integrated into the genome by reinfection and retrotransposition (Gifford and Tristem, 2003). 
The human genome project of 2001 identified several thousands HERVs in the human genome based on 
sequence comparisons with known mammalian retroviruses (Gifford RJ, 2006; Lander et al., 2001). 
Human endogenous retroviruses are classified into three classes because of their similarities with beta, 
gamma or spumaviruses. The subdivision into HERV subclasses usually follows the primer binding site, 
which defines the specific tRNA that acts as a primer for the reverse transcriptase. In the case of HERV-
K, the lysine tRNA serves as a primer (Andersson et al., 1999; Bock and Stoye, 2000). The best preserved 
elements belong to the HERV-K (HML-II) family and are classified as betaretroviruses based on their 
relationship to the exogenous mouse mammary tumor viruses (MMTV). HML stands for ‘human MMTV-
like’ (Hohn et al., 2013; Hohn et al., 2016). 
HERVs play an important physiological and pathological role. In 1992 the physiological influence of the 
5’LTR of HERV-E on the expression of its from C-terminal α-amylase gene could be detected. The 
promotor function of the LTR thereby enhances the production of the sugar-splitting enzymes of the 
salivary gland and thus leads to a faster utilization of carbohydrates in the diet (Ting et al., 1992). 
Another example is the env genes of HERV-W and HERV-FRD, better known as syncytin-1 and syncytin-2, 
which influence placental development (Bannert et al., 2018). Syncytin-1 is involved in the fusion of the 
cytotrophoplasts cells and thus leads to the formation of the polynuclear syncytiotrophoblast (Blond et 
al., 1999; Blond et al., 2000; Mi et al., 2000; Pötgens et al., 2004). Syncytin-2 carries through its 
immunosuppressive properties of mother-to-child tolerance during pregnancy (Malassiné et al., 2007). 




cytotrophoblast, but not in the sncytiotrophoblast. One also suspects immunosuppressive properties 
and thus a protective function against fetal rejection by the maternal immune system (Kämmerer et al., 
2011). However, HERV-K has also been pathologically linked to germ cell tumors and melanomas 
(Büscher et al., 2005; Götzinger et al., 1996; Krone and Grange, 2010). But other HERVs also play an 
important role in disease education. In prostate cancer an increased expression of the envelope protein 
of HERV-E was found, but not in healthy tissue (Wang-Johanning et al., 2003). HERV-W is associated with 
multiple sclerosis and psychiatric disorders such as schizophrenia (Antony et al., 2011; Leboyer et al., 
2013). In addition, multiple sclerosis HERVs have been implicated in other autoimmune diseases, such as 
type 1 diabetes mellitus, rheumatoid arthritis and lupus erythematosus (Balada et al., 2010). 
 
1.2 Structure and replication of retroviruses 
1.2.1 Morphology of retroviral particles 
Retroviruses are enveloped viruses with a diameter of 80-120nm and possess aikosahedral, cylindrical or 
conical core. They consist of 65% proteins, 30% lipids, 3% carbohydrates and 2-3% RNA (Coffin JM. et al., 
1997; Vogt VM, Simon MN, 1999). Basically, a morphologically distinction is made between immature 
and mature, extracellular retroviral particles. Immature particles are released by cells and mature by 
processing of the polystructure protein gag by viral protease. Both forms have a viral envelope 
membrane enriched with sphingolipids, cholesterol and other components of lipid rafts (Aloia et al., 
1993; Quigley et al., 1971).  
 
Figure 3: Gag and Retrovirus assembly 
The cartoon shows three stages in retrovirus morphogenesis: a partially assembled particle on the host cell plasma membrane, 
an immature particle that is composed of a paracrystalline gag structure and a mature virus particle that has a distinct core. Gag 
is a polyprotein including matrix (MA), capsid (CA) and nucleocapsid protein (NC) domains. Env represents the trimeric 




Their surface is also homogeneously associated with viral, glycosylated envelope protein which spans 
the viral transmembrane protein consisting of about 20 hydrophobic amino acids (Özel et al., 1988). 
Below the viral membrane of immature particles is a homogeneous layer which is formed by the 
precursor protein gag. It accounts for about three quarters of the protein content of viral particles and 
shows itself in transmission electron microscopy as an electron-dense layer under the envelope 
membrane (Coffin JM. et al., 1997). If the precursor protein gag is split into its individual structural 
proteins as part of the maturation by the viral protease, mature particles are formed. In contrast to the 
immature particles, these are characterized by an electron-dense core. After maturation, the matrix 
protein remains close to the membrane. The capsid proteins form into the virus core, the capsid. It has 
the ribonucleoprotein complex, consisting of two homologous RNA single plus strands and nucleocapsid 
proteins that bind and condense the RNA (Nermut and Hockley, 1996). In addition, the capsid contains 
other viral proteins, such as the reverse transcriptase, the integrase and the viral protease.  
 
Figure 4: Schematic construction of an HIV particle  
Lipid membrane with heterodimeric complex of membrane glycoproteins gp41 and gp120; Matrix consisting of matrix proteins 
p17; Capsid consisting of capsid proteins p24; Ribonucleoprotein complex consisting of nucleocapsid protein p7, reverse 
transcriptase, viral RNA genome and integrase; accessory proteins viral infectivity factor  (Vif), viral protein rapid (Vpr), viral 
protein out (Vpu) and negative factor (Nef) (source: eenzyme). 
 
1.2.2 Viral genome and provirus 
Retroviruses have a 7 to 12 kilo base (kb) genome consisting of two homologous RNA single strands in 
the plus strand orientation. The genome of the retroviruses basically consists of the four genes gag, pro, 
pol and env. All genes having an open reading frame (ORF). The genes gag and env are structural genes. 
The gag gene creates the group specific antigen. It is a polystructure protein and includes the major 
structural proteins of all retroviruses: matrix, capsid and nucleocapsid protein (figure 3). In addition, 
most gag proteins have other proteins of different functions (Coffin JM. et al., 1997). They are located 




proteins have one or more L-domains and are therefore crucial for the budding and release of viral 
particles. The pro gene encodes the viral protease, pol the viral enzymes reverse transcriptase, integrase 
and RNaseH and env the envelope protein. Env is also a precursor protein consisting of signal peptide, 
surface glycoprotein and transmembrane protein. In contrast to the gag protein, it is processed before 
incorporation into viral particles (Coffin JM. et al., 1997; Kurth R. and Bannert N., 2010). Complex 
retroviruses also have regulatory genes. They lead to the expression of accessory proteins, which can 
influence host factors and decisively influence the replication cycle (Coiras et al., 2010). 
When the viral genome is integrated into the DNA of the host, it is called a provirus. The viral genes are 
flanked by an LTR, which are always in the same orientation (Reuss and Schaller, 1991). LTRs are 200 to 
600 base pairs long, regulatory DNA sequences that are essential for the integration or reintegration of 
retro elements into the host genome. In addition, they serve as a binding site for the transcription 
factors and contain all signal sequences for the initiation, amplification and control of gene expression. 
An LTR is composed of U3 region, which includes promotor and enhancer, R region and U5 region. The 
viral RNA is flanked at the 5’ end by a 5’ cap structure followed by R and U5 regions. Behind the U5 
region is directly the primer binding site (tPBS) for the cell own transfer RNA. This initiates reverse 
transcription since the tRNA acts as a primer in this case. The tPBS follows the Ψ site, the packaging 
signal of the retroviral RNA. At the 3’ end of the viral RNA is the R and U3 regions with a 3’ 
polyadenylation, also termed as poly-A-tail.  
 
Figure 5: General structure of a retroviral genome 
The long terminal repeats (LTRs) have sequences needed for the regulation and initiation of transcription within the unique 







1.2.3 Replication cycle 
The replication of retroviruses begins by infection of the host cell. The virus, mediated by its 
glycosylated cot proteins, attaches to specific receptors of the cell. It leads to the fusion of the virus 
envelope with the plasma membrane or to the endocytosis of the entire viral particle. Upon entry into 
the cell, the envelope-less capsid undergoes a conformational change, releases some of its subunits and 
becomes permeable to nucleotides (Modrow S. et al., 2009). This reverse transcriptional complex 
includes the ribonucleotide complex associated with the reverse transcriptase. The binding of the 
specific tRNA to the primer binding site of the viral RNA initiates the process of reverse transcription. 
The viral genetic information is transcribed into double-stranded, proviral DNA. The viral RNA is 
subsequently hydrolytically degraded by the viral RNaseH. The resulting pre-integration complex of 
proviral DNA and proteins is transported in the lentiviruses from the cytoplasm through the nuclear 
pores into the cell nucleus. These include nuclear import factors as well as accessory viral proteins, such 
as Vpr in HIV-1 (Bukrinsky et al., 1993; Freed, 2001). Pre-integration complexes of other retroviruses are 
only able to migrate into the cell nucleus during mitosis, since nuclear-transport-promoting factors are 
lacking. In the nucleus, the proviral DNA then integrates into the euchromatic host genome via 
integrase. This can lead to the destruction, inactivation or activation of cell genes. The integration of the 
provirus is essential for the expression of viral proteins and is inherited by cell division (Weiss, 2006). 
When transcription of viral genes occurs, depending on the activity state of the host cell, various viral 
mRNA species are observed (Reed, 2003).  
On the one hand, this is the full-length mRNA, which is also available as a viral genome due to the 
packaging signal. Their translation leads to the synthesis of the precursor proteins gag, gag-pro and gag-
pro-pol (Bannert and Kurth, 2004; Swanstrom and Wills, 1997). On the other hand, it’s possible to find 
single and multiple spliced mRNA. Splicing is an essential process to produce multiple proteins encoded 
in a transcript independently expressing each other (Bodem et al., 2011). In addition, due to cellular 
control mechanisms, only spliced mRNA can be exported from the cell nucleus. To get around this, 
complex retroviruses have specific shuttle proteins that allow the transport of viral full-length mRNA 
into the cytoplasm (Cullen, 2002; Hanke et al., 2013; Wodrich and Kräusslich, 2001). The expression of 
almost all viral proteins takes place on free, in the cytoplasmic ribosomes or ribosome chains 
(polysomes) instead (Tritel and Resh, 2000). The transport of the viral proteins is then carried out 
directly or via endosomal transport pathway to the plasma membrane. The precursor protein env, on 
the other hand, is formed on the rough endoplasmic reticulum (rER) by translation of single spliced 
mRNA and integrated directly into the ER membrane (Checkley et al., 2011; Teissier et al., 2010). This is 
followed by vesicular transport via the trans-Golgi network to the plasma membrane. Depending on the 




membrane and mature extracellularly by processing the gag precursor proteins by means of viral 
protease (George et al., 2011; Kraus et al., 2011; Ono, 2009).  
 
Figure 6: HIV replication cycle  
The replication cycle of retroviruses begins with the receptor-dependent binding of the virus to the host cell. Depending on the 
virus, the capsid is internalized by the fusion of the viral envelope with the cell membrane or endocytosis. The transcription of 
single-stranded RNA into double-stranded DNA is carried out by means of reverse transcriptase in the complex. The resulting 
pre-interglacial complex is imported into the nucleus and the viral genome is integrated into the host DNA as a provirus. The 
mRNA resulting from the transcription of the viral DNA is partially differentially spliced before nuclear export and serves for 
protein expression. Full-length mRNA and viral proteins assemble on cellular membranes into viral particles. These are released 
and mature extracellularly (Jmarchn, 2017). 
 
1.2.4 Entry of HIV in the target cell 
The entry of HIV into the host cell is mediated by the interaction of the virus with the CD4 receptor and 
another chemokine receptor. The CD4 receptor is a T-cell receptor which is used to display antigens on 
the T-cell and interacts with the major histocompatibility complex II (MHC II) of the immune system. The 
virus binds with the immunodominant V3 loop of the external glycoprotein gp120 to the monomeric 
glycoprotein receptor CD4. This is present on the cell surface of T-lymphocytes, Monocytes and 
macrophages (Bowers et al., 1997). After the interaction between gp120, CD4 and subsequently also the 
appropriate co-receptor, the resulting cascade of conformational changes causes membrane fusion 
through the transmembrane glycoprotein gp41 is initiated. The chemokine receptors are subdivided 
according to the amino acid motifs of their natural ligands into the following groups: CXC, CC, CX3C or C. 
HIV can interact with different co-receptors, because of its variability. Currently, HIV is differentiated 
into two major variants after use of the co-receptor. The T-cell tropics HIV isolate (X4 virus) use the 
chemokine receptor CXCR4, while the macrophage-tropic isolate (R5 virus) use the receptor CCR5 (Deng 
et al., 1996; Feng et al., 1996). However, HIV can also use other so-called alternative co-receptors 





Figure 7: Human immunodeficiency virus (HIV) co-receptors. 
When the HIV glycoprotein gp120 binds to CD4 (a), it induces a conformational change in gp120 that exposes the co-receptor 
binding site (b); this is a complex domain comprising the V3 loop and specific amino-acid residues in CD4, collectively termed 
the “bridging sheet”. Exposure of the co-receptor binding site permits binding of gp120 to the co-receptor (c). Co-receptor 
binding induces conformational change in gp41 and insertion of the fusion peptide into the host cell membrane (Clercq, 2007). 
 
1.3 Heparan sulfate proteoglycans 
HSPG´s are a group of proteins which belongs to the group of glycosaminoglycan’s and have at least one 
covalently linked heparan sulfate (HS) side chain. The basic structure of the unbranched HS side chains is 
an alternating sequence of glucuronic acid and N-acetylglucosamine, which are linked to beta-1,4- and 
alpha-1,4-glycosidically. The polymer is modified at various points by sulfation and epimerization. 
Because of the variability of these modifications, there are approximately thirty different disaccharides, 
and thus probably the formation of the most complex polysaccharides in mammalian cells (Esko, 1991; 
Kjellén and Lindahl, 1991). The modifications result in greater conformational flexibility and a strong 
negative charge, thereby supporting the electrostatic binding interactions of the proteoglycans. Some of 
these interactions are very specific and are mediated by defined sugar sequences within HS side chains 
(Turnbull et al., 1992). 
The primary structure of various heparan sulfate proteoglycans was determined by cloning of cDNAs. As 
a result, two forms of membrane associations could be detected. On the one hand anchoring via a 
transmembrane domain (syndecan family), on the other hand binding via GPI to the plasma membrane 




The family of syndecans consists of syndecan-1, syndecan-2 or fibroglycan, syndecan-1 or N-syndecan 
and syndecan-4, also called amphiglycan (David et al., 1990). All syndecans have an extracellular domain 
whose sequence similarity of 10 to 20%. The transmembrane domain and the short cytoplasmic domain 
of these four proteins, on the other hand, have 60-70% sequence similarity. The transmembrane 
domain is responsible, among other things, for the formation of cell surface complexes (Asundi and 
Carey, 1997). Syndecan-1 is the predominant proteoglycan in epithelial cells. In fibroblasts, on the other 
hand, it is of little importance and it is still expressed at certain times during embryonic development 
(Kim et al., 1994). In addition to heparan sulfates syndecan-1 also has chondroitin sulfates. Syndecan-2 
is found mainly on fibroblasts and endothelial cells, while it lacks in most epithelial cells. In contrast, 
syndecan-4 is a ubiquitous proteoglycan (David et al., 1990). 
HS side chains bind a variety of growth factors, extracellular matrix factors and other proteins, indicating 
that HS side chains bind to cell adhesion or regulation of cell division activity (Carey, 1997). In addition, it 
is known that various pathogens interact with the HS side chains. This includes the binding of the human 
cytomegalovirus (Compton et al., 1993) and herpes simplex virus (Shieh, 1992), the binding of the 
bacteria Borrelia burgdorferi (Isaacs, 1994), Chlamydia trachomatis (Chen et al., 1996), Staphylococcus 
aureus (Liang et al., 1995) and the protozoa Leishmania (Love et al., 1993) and Trypanosoma cruzi 
(Ortega-Barria and Pereira, 1991). 
 
1.4 Aim of the work 
The human genome consists of about 8% endogenous retroviruses, some of them are highly conserved 
to generate functional proteins and viral particles. Probably the best preserved proviruses belong to the 
family HERV-K (HML-2). For viral infection, the expression of functional HERV-K (HML-2) envelope 
proteins is of crucial importance. These not only mediate the first cell contact, initiate the fusion of virus 
and host membrane, but also determine the host specificity for the infection of a particular tissue, cell 
type or organism. Endogenously expressed HERV-K (HML-2) envelope proteins are also able to be 
incorporated into foreign retroviruses and thus alter their cell tropism. 
Because of the specificity of viral coat proteins, it is important to understand which structures and 
receptors facilitate the virus entry into the host cell. For this reason, the aim of the work is to examine 
different receptors on the host cell and to determine which of these proteins are responsible for the 
entry of HERV-K (HML-2). In order to investigate differences in the entry of viral particles, various 
membrane-bound receptors are to be overexpressed in a selected cell line. This overexpression should 




brought into the cells by PEI transfection, because a high transfection efficiency is to be expected. Due 
to the different protein tags of the receptors, they can be analyzed by western blots or EGFP 
fluorescence. Since the modified viruses have the ability to form luciferase within the cell, a luciferase 
assay is used to determine the amount of viral infection. 
Due to the broad tropism of HERV-K, it can be concluded that ubiquitous membrane-bound 
macromolecules, rather than tissue-specific proteins, are candidates for cellular receptors that mediate 
viral binding or entry into the cell. Therefore, another goal of this work is to study the function of one of 
the important glycosaminoglycan’s. Heparan sulfate is a ubiquitous, highly negatively charged 
extracellular matrix polysaccharide involved in many biological processes. It is bound as a proteoglycan 
together with transmembrane or membrane-anchored proteins, forming the heparan sulfate 
proteoglycan (HSPG). The highly negatively charged environment may have a positive or negative 
influence on viral heparan sulfate binding proteins in order to reach the cell membrane for viral entry. 
To analyze the effect of heparan sulfate, the viruses and cells are incubated with various concentrations 
of heparan sulfate. After infection with special viruses, the luciferase assay is used to determine 
whether heparan sulfate has a positive or negative influence on the viral entry. Furthermore, an 
enzymatic digestion by heparinase I and III, as well as the change in sulfation with sodium chlorate, the 
cell surface is changed with respect to heparan sulfate. Here, a significant decrease in viral entry into the 
cell should be visible. The cell surface alteration is detected by various western blots, using antibodies 
like anti-syndecan-1 and anti-heparan sulfate. Overexpression by transfection of plasmids or down 
regulation by syndecan-1 shRNA could be further evidence for the involvement of heparan sulfate in the 
entry of HERV-K (HML-2). 
By these two approaches on the one hand a specific entry of the virus by receptors is examined and on 
the other hand an interaction with glycosaminoglycan’s on the host cell with certain binding proteins on 
the viral envelope. Because of the different methods, a broad experimental spectrum is available, which 
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2. Material and Methods 
2.1 Material 
2.1.1 Equipment 
TABLE 1: Device list 
Equipment  Company 
Balance Sartorius, Göttingen, Germany 
Balance PR803 Mettler Toledo, Ohio, USA 
Biofuge Heraeus Prima R Thermo Fisher Scientific, Schwerte, Germany 
Centrifuge 4K15 Sigma Aldrich, Steinheim, Germany 
Centrifuge 5415D Eppendorf, Hamburg, Germany 
Electrophoresis Chamber Bio Rad, München, Germany 
ELISA Reader Sunrise  Tecan Group, Männedorf, Switzerland 
Fluorometer Qubit 3  Life Technologies, California, USA 
Incubator Hera Cell 240  Thermo Fisher Scientific, Schwerte, Germany 
Incubator Shaker C24 New Brunswick Scientific, New Jersey, USA 
Luciferase Reader Centro LB960  Berthold Technologies, Bad Wildbad, Germany 
Microscope Eclipse TS100 Nikon, Tokio, Japan 
Multiskan GO Thermo Fisher Scientific, Schwerte, Germany 
Nanodrop 1000 peQLab, Erlangen, Germany 
Odyssey Li-Cor Biosciences, Nebraska, USA 
pH Meter MP220 Mettler Toledo, Ohio, USA 
Power Pac Basis and HC Bio Rad, München, Germany 
Thermo Stat Plus Shaker Eppendorf, Hamburg, Germany 
Thermomixer 5436 Eppendorf, Hamburg, Germany 
Trans Blot SD Bio Rad, München, Germany 
Transilluminator GelDoc Phase, Lübeck, Germany 
Ultra-Low Freezer U57085 New Brunswick Scientific, New Jersey, USA 
Ultracentrifuge Optima L-100K  Beckman Coulter, California, USA 









TABLE 2: List of consumables 
Product   Company 
6-well Plates  TPP, Trasadingen, Switzerland 
96-well Plates for Cell Culture TPP, Trasadingen, Switzerland 
96-well Plates for ELISA Thermo Fisher Scientific, Schwerte, Germany 
96-well Plates for Luciferase Assay Thermo Fisher Scientific, Schwerte, Germany 
Cell Culture Dish 15cm TPP, Trasadingen, Switzerland 
Cell Culture Flask T75 and T150 TPP, Trasadingen, Switzerland 
Cell Scrapers 24cm and 30cm TPP, Trasadingen, Switzerland 
Clip Tips Thermo Fisher Scientific, Schwerte, Germany 
Cryo.S Tubes Greiner Bio-One, Kremsmünster, Austria 
Falcon Tube 15ml and 50ml TPP, Trasadingen, Switzerland 
Filter Tips Eppendorf, Hamburg, Germany 
Pipette Tips Thermo Fisher Scientific, Schwerte, Germany 
Reaction Tubes 1.5ml and 2ml Eppendorf, Hamburg, Germany 
Serological Pipette TPP, Trasadingen, Switzerland 
Sterilcup and Steriltop Merck, Darmstadt, Germany 
Sterile Filter 0.45µm Sartorius Stedim Biotech, Goettingen, Germany 
Sterile Syringe Omnifix 50ml Braun, Melsungen, Germany 
Ultra-Clear Centrifuge Tube Beckman Coulter, California, USA 
X-ray Film Kodak, Rochester, USA 
 
2.1.3 Chemicals 
TABLE 3: Chemicals that are not from the company Roth. 
Product  Company 
Albumin Standard 2mg/ml Thermo Fisher Scientific, Schwerte, Germany 
Ammonium Persulfate Thermo Fisher Scientific, Schwerte, Germany 
Carbonate-Bicarbonate Tablet Sigma Aldrich, Steinheim, Germany 
cOmplete Protease Inhibitor Cocktail Sigma Aldrich, Steinheim, Germany 
Dimethyl Sulphoxide Hybri-Max Sigma Aldrich, Steinheim, Germany 
DMEM High Glucose Robert Koch Institut, Berlin, Germany 
Ethidium Bromide Solution Sigma Aldrich, Steinheim, Germany 
FBS Superior S0615/0114G Biochrome, Berlin, Germany 
Glutamine 200mM Biochrome, Berlin, Germany 
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Hams´s F12 Robert Koch Institut, Berlin, Germany 
Heparan Sulfate 5mg Sigma Aldrich, Steinheim, Germany 
HIV-Standard 290ng/ml Robert Koch Institut, Berlin, Germany 
Hydrogen Peroxide Solution 30% (w/w) Sigma Aldrich, Steinheim, Germany 
LB Medium Robert Koch Institut, Berlin, Germany 
o-Penylenediamine Dihydrochloride 5mg Sigma Aldrich, Steinheim, Germany 
Penicillin/Streptomycin (P=10000U/ml and 
S=10000µg/ml) 
Gibco by Life Technologies, California, USA 
Phosphate-Citrate Tablet Sigma Aldrich, Steinheim, Germany 
Polyethylenimine, branched Sigma Aldrich, Steinheim, Germany 
RPMI 1640 Robert Koch Institut, Berlin, Germany 
Separating Gel Buffer 1.5M Tris-HCL Bio Rad, München, Germany 
Stacking Gel Buffer 0.5M Tris-HCL Bio Rad, München, Germany 
Triton-X100 Sigma Aldrich, Steinheim, Germany 
Trypsin (0.05%)/EDTA (0.02%) Solution Biochrome, Berlin, Germany 
 
2.1.4 Cell culture media 
 
Dulbecco's Modified Eagle's Medium (DMEM) 
 1 x DMEM High Glucose   
 10 % (v/v) Fetal Bovine Serum (FBS)   
      
 
RPMI 1640 
 1 × RPMI 1640   




 1 × Ham´s F12   
 10 % (v/v) Fetal Bovine Serum (FBS)   
 4,0 mM Glutamine   
      
 
Freezing Medium 
 10 % (v/v) DMSO   
 90 % (v/v) Fetal Bovine Serum (FBS)   
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2.1.5 Buffers and solutions 
 
Tris-NaCl-EDTA Solution (TNE) 
 10 mM Tris   
 1 mM EDTA   
 100 mM NaCl pH 7.5  
 
50× Tris Acetat EDTA Buffer (TAE) 
 2 M Tris base   
 250 mM Sodium acetate   
 60 ml/l Acetic Acid   
 50 mM EDTA pH 7.8  
 
Heparinase I Buffer 
 20 mM Tris-HCL   
 50 mM NaCL   
 4 mM CaCl2   
 0.01 % BSA   
  in Aqua dest. pH 7.5  
 
Heparinase III Buffer 
 20 mM Tris-HCL   
 4 mM CaCl2   
 0.01 % BSA   
  in Aqua dest. pH 7.5  
 
For Western Blot Analysis 
 
NP-40 Cell Lysis Buffer 
 50 mM Tris-HCL   
 150 mM NaCl   
 1 % NP-40   
 1 x Protease inhibitor pH 8.0  
 
RIPA Lysis Buffer 
 50 mM Tris-HCL   
 150 mM NaCl   
 0.1 % SDS   
 0.5 % Sodium Deoxycholate   
 1 % NP-40 (or Triton X-100)   
 1 x Protease inhibitor pH 8.0  
 
10x Tris-Glycine Buffer 
 30.3 g/l Tris   
 144.1 g/l Glycine   
 to 1 l Aqua dest.   
 
 




 100 ml 10x Tris-Glycine Buffer   
 200 ml Methanol   
 to 1 l Aqua dest.   
 
PBS-T 
 0,001 % Tween-20   
  in 1x PBS   
 
Blocking Solution 
 50 g/l Milk powder   
  in Aqua dest.   
 
10x Running Buffer 
 30.3 g/l Tris   
 144.1 g/l Glycine   
 10 g/l Sodiumlaurylsulfate (SDS)   
  in Aqua dest. pH 8.3  
 
Lämmli Buffer 
 20 g/l SDS   
 50 ml/l Β-Mercaptoethanol   
 250 ml/l Glycerol   
 125 ml/l Stacking Buffer   
 0,01 % Bromphenolblue   
  in Aqua dest. pH 6.8  
 
6x DNA Loading Buffer 
 60 % (v/v) Glycerol   
 0.2 % (w/w) Orange G   
 60 mM EDTA pH 7.6  
 
12% Stacking Gel 
 7.9 ml Aqua dest.   
 9.6 ml 30% Acrylamide   
 6 ml 1.5M Tris   
 240 µl 10% SDS   
 240 µl 10% APS   
 24 µl TEMED   
 
4% Stacking Gel 
 8.9 ml Aqua dest.   
 2 ml 30% Acrylamide   
 3.75 ml 0.5M Tris   
 150 µl 10% SDS   
 150 µl 10% APS   
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For p24 ELISA 
 
Carbonate/Bicarbonate Buffer 
 1 Tabl. Carbonate/Bicarbonate   
 100 ml Aqua dest.   
 
Phosphate/Citrate Buffer 
 1 Tabl. Phosphate/Citrate   
 100 ml Aqua dest.   
 
Blocking Buffer 
 2 % milk powder   
 1 x 1x PBS   
 
Tween Solution 
   2 % milk powder   
 0,05 % Tween-20   
 1 x 1x PBS   
 
Substrate Solution 
 5 mg OPD   
 12 µl 30% H2O2   
 12,5 ml Phosphate/Citrate Buffer   
 
2.1.6 Cell lines 
TABLE 4: used cells 
Cells Origin Medium Place in N 
COLO 205 Colon RPMI T1, To2, B4, L7 
HCT 116 Colon RPMI T1, To2, B4, L4 (1-5) 
HEK 293T Kidney DMEM T1, To2, B4, L2 
Sk-Mel 28 Melanoma DMEM T1, To2, B4, L5 (1-5) 
















TABLE 5: used antibodies 
Antibody Species Concentration Company 
Anti-Flag Mouse (M) 1:1000 Sigma Aldrich, Steinheim, 
Germany 
Anti-GAPDH Rabbit (M) 1:5000 Biolegend, California, USA 
Anti-HA Mouse (M) 1:1000 Biolegend, California, USA 
Anti-HA Mouse (M) 1:1000 Cell Signaling, 
Massachusetts, USA 
Anti-Heparan Sulfate  Mouse IgM (P) 1:200 Amsbio, Abingdon, UK 
Anti-His Mouse (M) 1:1000 Sigma Aldrich, Steinheim, 
Germany 
Anti-p24 Mouse (M) 1:250 Sigma Aldrich, Steinheim, 
Germany 
Anti-Syndecan-1 (A-6) Mouse (M) 1:200 Santa Cruz, California, USA 
Anti-V5 Mouse (M) 1:5000 Bio Rad, München, 
Germany 
Coating Ab AG3.0 Human 1:1000 RKI, Berlin, Germany 
HIV Poolserum (First Ab) Human  1:5000 RKI, Berlin, Germany 
Sec.Ab IRDye 680T Goat Anti-Mouse 
(P) 
1:20000 Li-Cor Biosciences, 
Nebraska, USA 
Sec.Ab IRDye 800CW Goat Anti-Mouse  
(P) 





TABLE 6: List of used kits 
Product Company 
One Shot Top10 Thermo Fisher Scientific, Schwerte, Germany 
Pierce BCA Protein Assay Kit Thermo Fisher Scientific, Schwerte, Germany 
Plasmid Maxi Kit (25) Qiagen, Hilden, Germany 
Qubit 3 Reagents Life Technologies, California, USA 
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2.1.9 Ready reagents 
TABLE 7: used ready reagents 
Product Company 
Loading Dye 6x Thermo Fisher Scientific, Schwerte, Germany 
GeneRulerTM 1 kb DNA Ladder Thermo Fisher Scientific, Schwerte, Germany 
GeneRulerTM 1 kb+ DNA Ladder Thermo Fisher Scientific, Schwerte, Germany 
GeneRulerTM 100 bp+ DNA Ladder Thermo Fisher Scientific, Schwerte, Germany 
Gold Protein Marker IV peQLab, Erlangen, Germany 
Page Ruler Prestained Protein Ladder Thermo Fisher Scientific, Schwerte, Germany 
Passive Lysis Buffer 5x Promega, Madison, USA 
Phosphate Buffered Saline (PBS) Robert Koch Institute, Berlin, Germany 
Rapid Detection of Firefly Luciferase Promega, Madison, USA 
2.1.10 Enzymes 
TABLE 8: List of the used enzymes 
Product Company 
BamH I New England Biolabs, Massachusatts, USA 
Bgl II New England Biolabs, Massachusatts, USA 
Heparinase I - 50U Sigma Aldrich, Steinheim, Germany 
Heparinase III - 10U Sigma Aldrich, Steinheim, Germany 
Hind III New England Biolabs, Massachusatts, USA 
NotI New England Biolabs, Massachusatts, USA 
Pstl I New England Biolabs, Massachusatts, USA 
SaC I Thermo Fisher Scientific, Schwerte, Germany 











TABLE 9: used plasmids 
Plasmid Concentration in ng/µl Description 
BC-GPR56 1006 G-protein coupled receptor 56 
CD63-pEGFP-C2 1070 Lysosomal-associated membrane protein 3 
Env Syncytin-1 V5-Tag 2900 Viral envelope for Syncytin-1 
Env Syncytin-2 V5-Tag 2800 Viral envelope for Syncytin-2 
GPR161-Tango 984 G-protein coupled receptor 161 
GPR56 (ADGRG1) 728.5 G-protein coupled receptor 56 
MMTV-Co-Env-V5 1052 Viral envelope for MMTV 
orico env Δc1 1943 Viral envelope for HERV-K 
orico env Δc1 (R140C) 1739 Viral envelope for inactive HERV-K 
pcAG NL1 (-) 1017 Neurologin-1 receptor 
pCMV-VSV-G Myc 1684 Viral envelope for VSV-G 
pCMV-VSV-G-Mut (P127D) 755 Viral envelope for inactive VSV-G 
phL1A pcDNA3 (L1CAM) 1040 Neural cell adhesion molecule L1 
pLVX-MFSD2A-myc 2567 Receptor for syncytin-2 
psPAX2 1613 2nd generation lentiviral packaging plasmid 
pWPXL-GFP 2024 2nd generation lentiviral transfer plasmid 
Sc-36587-SH 100 Syndecan-1 shRNA 
SLC1A4 (=ASCT1) 2100 Receptor for syncytin-1 
SLC1A5 (=ASCT2) 1800 Receptor for syncytin-1 
SORT1-bio-His 1056 Sortilin-1 receptor 
 
2.1.12 HIV pseudotyped viruses 
TABLE 10: produced pseudotyped HIV´s 
Virus P24 Concentration in ng/µl 
HERV R140C 11.07 











2.2.1 Cell biological methods 
2.2.1.1 General culture conditions 
As described in table 4, all cells were cultured in DMEM or RPMI with 10% FCS and 50 U/ml penicillin 
and 50µg/ml streptomycin under standard cell culture conditions (37°C, 5% CO2) in cell culture flask. 
Furthermore, the cell culture conditions in this work were adapted to the use of sodium chlorate. For 
this purpose, several preliminary tests were carried out to allow a proper use of sterile sodium chlorate. 
TABLE 11: plated cell number for different dishes and plates 
 cell number 
10cm dish 4x106 cells/dish 
15cm dish 9x106 cells/dish 
96-well plate 1.2x104 cells/well 
6-well plate 5x105 cells/well 
 
2.2.1.2 Determination of the cell number 
To count the cells 10 µl of the resuspended cells were transferred to a Neubauer counting chamber and 
four large squares were counted in a meandering fashion. 
𝒄𝒐𝒖𝒏𝒕𝒆𝒅 𝒄𝒆𝒍𝒍𝒔
𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒍𝒂𝒓𝒈𝒆 𝒔𝒒𝒖𝒂𝒓𝒆𝒔
 × 𝟏𝟎𝟒 (𝒄𝒉𝒂𝒎𝒃𝒆𝒓 𝒇𝒂𝒄𝒕𝒐𝒓) × 𝒅𝒊𝒍𝒖𝒕𝒊𝒐𝒏 =  𝒙 𝒄𝒆𝒍𝒍𝒔/𝒎𝒍 
 
2.2.1.3 Trypsinization of adherent cells 
To detach the cells from the bottom of the cell culture flask, the medium was aspirated and the cells 
were washed with PBS. After addition of 2ml of trypsin/EDTA and an incubation time of 5 minutes at 
37°C, the cells dissolved and could be gently and continuously resuspended in 8ml of medium so that 
cell aggregates were dissolved. This cell suspension was used for sub culturing as well as for 
experiments.   
2.2.1.4 Centrifugation 
Unless otherwise described, cells were centrifuged at room temperature and 300 x g for 5 minutes. 
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2.2.1.5 Thaw and freeze of cells 
In order to ensure a long-term use of a cell lines, a part of this after re-thawing and about two times 
passaging was frozen again. For this purpose, the excess of cells after passaging once washed in PBS and 
centrifuged. The cell pellet of a 75cm² cell culture flask was then resuspended in a certain volume of 
freezing medium. Of these, 1ml with 1x106 cells were transferred in a cryotube and cooled down slowly 
to -80°C over a period of 24 hours with an isopropanol-filled freezing container in order to ensure cell-
friendly freezing. The storage of the cell lines took place permanently in a tank with liquid nitrogen at  
-196°C. To thaw cells stored in liquid nitrogen, they were gently warmed in a water bath at 37°C and 
resuspended in 5ml of complemented DMEM. After pelleting the supernatant was discarded and the cell 
pellet resuspended in 12ml of the right medium. The further cultivation was carried out as described in 
section 2.2.1.1. The freezing and thawing of cell lines was under sterile conditions.  
2.2.1.6 PEI transfection 
In transfection, plasmid DNA is transiently or permanently introduced into eukaryotic cells by various 
methods. The transfection of the cells was carried out at the earliest one day after seeding in the culture 
vessel in order to ensure a good adherence of the cells to the bottom. The cells showed a spreading 
morphology and a confluence of 50-80%.  
Polythylenimine is a stable cationic polymer and condenses DNA into positively charged particles that 
bind to anionic cell surfaces. Consequently, the DNA:PEI complex is endocytosed by the cells and the 
DNA released into the cytoplasm (Sonawane et al., 2003). 
Prior to transfection bring all reagents to room temperature. In a sterile tube dilute total plasmid DNA in 
serum-free DMEM (volume is 10% of the final volume of the culture vessel). By viral production use a 
plasmid ratio of 4:3:1 (Backbone:Packaging:Envelope). Add PEI to the diluted DNA and mix immediately 
by vortexing or pipetting. The volume of used PEI is based on a 3:1 ratio of PEI (µg):total DNA (µg). After 
an incubation time of 15 minutes at room temperature add the DNA/PEI mixture dropwise to the rest of 
the medium (can contain antibiotics) with adherent cells. After 8-24 hours the PEI/DNA mixture can be 
replaced with fresh medium. Harvest transfected cells or viral supernatants at 48 hours post-
transfection. Every transfection was checked with a specific plasmid that generated a GFP signal and 
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TABLE 12: PEI transfection protocol per well 
 DNA PEI (2.5µg/µl) Medium 
96-well plate 0.1µg 0.12µl 20µl 
6-well plate 3µg 3.6µl 200µl 
15 cm dish 12µg 14.4µl 2000µl 
 
2.2.1.7 Viral infection 
For the entry experiment, cells were seeded in 96-well plates and cultured for 24 hours. Thereafter, the 
medium was removed and overlaid with 50ul of new medium. This medium contained the virus with a 
p24 concentration of 100ng per well. Due to the high infection rate of VSV, only 1ng / well virus was 
used. After a one-hour incubation at 37 ° C, the viral medium was removed, the cells washed with PBS 
and cultured for an additional 48 hours under standard cell culture conditions. During this time, the 
luciferase could be formed, which was then quantified. 
2.2.1.8 Production of viral stocks 
To prepare viral stocks, the supernatant was removed from various 15 cm dishes after transfection and 
sterile filtered with a 0.45 µm filter. This will remove any cell debris and leave only the smallest 
components in the medium. For purification, 5ml of 20% sucrose was placed in an Ultra Clear Centrifuge 
tube and carefully pipetted about 30 ml supernatant on it, resulting in two phases. After ultra-
centrifugation at 32,000 RPM for 3 hours at 4°C, the medium was decanted and the pellet resuspended 
in about 200-300 µl 1xPBS. The viruses were stored after aliqouting at -80°C. 
2.2.1.9 Incubation with heparan sulfate 
In order to analyze the occurrence of viruses by means of heparan sulfate proteoglycans, cells and 
viruses were incubated with different concentrations of heparan sulfate and after this the viral entry 
inside the cells was examined. For this experiment, cells were seeded in a 96-well plate and cultured for 
24 hours at standard cultivation conditions. Thereafter, the viruses were incubated for one hour at 37°C 
with four different concentrations of heparan sulfate (HS). For this, 50 µl HS and 50 µl virus were mixed, 
resulting in a concentration of 400 µg/ml, 200 µg/ml, 100 µg/ml and 50 µg/ml. After this one-hour 
incubation, the HS/virus mixture was added to the cells and stored for a further hour at 37°C. Thus, the 
cells were incubated with 100ng of virus (1ng for VSV-G) and a certain concentration of HS. After the 
solution was removed and the cells were washed with 1xPBS, they were cultivated for another 48 hours 
before being processed for the luciferase measurement.  
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2.2.1.10 Cultivation with sodium chlorate 
Cells were cultivated for more than 2 passages with low sulfated Ham´s F12 growth medium and 25mM, 
50mM and 100mM sodium chlorate. Fresh sodium chlorate was added to each medium change. After 
the long-time incubation the cells were seeded in 96-well plates with the same medium and 24 hours 
later incubated with 100ng virus (1ng for VSV-G). After the solution was removed and the cells were 
washed with 1xPBS, they were cultivated for another 48 hours before being processed for the luciferase 
measurement. 
2.2.1.11 Enzymatic digestion with heparinase I and III 
For this experiment, cells were seeded in a 96-well plate and cultured for 24 hours at standard 
cultivation conditions. The heparinase I and III (blend) was dissolved in Hep.I buffer and the 
concentrations of 0.00001mU/ml, 0.01mU/ml and 10mU/ml were adjusted. In order to allow an optimal 
reaction, the cells were incubated with in each case 50µl heparinase in Hep.I buffer (without medium) 
for one hour at 37°C, since a precise pH value is necessary in enzymatic reactions. After the solution was 
removed and the cells were washed with 1xPBS, they were cultivated for another 48 hours in standard 
medium before being processed for the luciferase measurement. 
2.2.1.12 Creation of growth curves 
To analyze the proliferation behavior of the cell line SK-Mel28 with sodium chlorate, growth curves were 
generated. For this purpose, a defined number of 6-well plates were seeded in parallel and counted at 
certain times over a certain period of time.  
For this experiment, three cell culture flask were trypsinized, the cell suspension pooled and the cells 
counted to determine the number of cells per ml. For each batch, cells were seeded into two 6-well 
plates with a cell number of 4x104 cells and incubated for 12 days at standard cell culture conditions. 
Every second day the medium was changed with fresh sodium chlorate. One well of each condition 
(table 14) was trypsinized and counted every day in a defined volume. The values obtained were plotted 
logarithmically, which makes it possible to determine the latency phase, exponential phase, stationary 
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TABLE 13: Different conditions for the growth curves with sodium chlorate in Ham´s F12 medium 
Conditions Composition 
1 0 mM NaClO3 
2 25 mM NaClO3 
3 50 mM NaClO3 
4 100 mM NaClO3 
 
2.2.1.13 shRNA transfection 
To silence target gene expression via RNA interference a short hairpin RNA was used. It´s an artificial 
RNA molecule with a tight hairpin turn, which binds to a specific RNA of the cell and blocks the 
translation procedure.  
To get the shRNA expression into the cell, the specific plasmid was delivered by PEI transfection. For 
this, a 6-well plate was seeded with cells and after 24 hours transfected with 1µg and 2µg shRNA (table 
15). To select the stable transfected cells from non-transfected cells the antibiotic puromycin was used 
in a cell specific concentration, because the plasmids have coded a puromycin resistant section. To 
select a specific puromycin concentration for HEK293T and SK-Mel28, a puromycin kill curve was 
created. For those two 6-well plates for each cell line was seeded and after 24 hours incubated with 
different concentrations puromycin. There was used the concentrations from 0-5µg/ml and incubated 
for 2 weeks. During this time every second day the medium was changed with fresh antibiotics and the 
minimal concentration at which the non-transfected cells died was used for the assay.  
For HEK293T a concentration of 1.5µg/ml and for SK-Mel28 a concentration of 1µg/ml was used. After a 
selection and cultivation for 1-2 weeks to get a larger amount of transfected cells, a 96-well plate was 
seeded and 24 hours later incubated with 100ng virus (1ng for VSV-G). After the solution was removed 
and the cells were washed with 1xPBS, they were cultivated for another 48 hours before being 
processed for the luciferase measurement. 
TABLE 14: PEI transfection protocol per well for shRNA 
shRNA DNA PEI (2.5 µg/µl) Medium 
Syndecan-1 1µg 1.2µl 200µl 
 2µg 2.4µl 200µl 
Fibronectin 1µg 1.2µl 200µl 
 2µg 2.4µl 200µl 
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2.2.2 Protein analytics 
2.2.2.1 P24 capture ELISA 
The p24 antigen capture ELISA is used to detect the Gag antigen of the HI virus.  
In the first step, the 96-well plate had to be coated with the monoclonal antibody AG 3.0. Since the 
production of the antibody takes place internally, each time the best concentration in tested for coating 
with an antigen standard. For coating the plate, the antibody was diluted in 5 ml of 
carbonate/bicarbonate buffer and 50µl was added to each well. The plate was stored in the fridge at 4°C 
overnight for incubation. The next day, the plate was washed three times with 1xPBS and the remaining 
binding sites on the plate were blocked by adding 100µl of blocking buffer to each well for 30 minutes at 
37°C. After incubation, the plate was washed again and the samples applied. The samples were the 
inactivated (with a final 0.2% Tween concentration) viruses. For this purpose, a 1:3 dilution series with 
buffer and samples was created on the plate and incubated again by 37°C for one hour. During the 
incubation period, the primary antibody was prepared, which was an HIV-1+ plasma pool serum and 
diluted 1:5000 in PMT. After adding of 50µl and a further incubation for one hour at 37°C the secondary 
antibody the plate was washed again three times with 1xPBS. The secondary HRP linked antibody was 
diluted 1:1000 with PMT, added (50µl/well) and incubated for 1 hour at 37°C. 50µl of the OPD-substrate 
solution was added after the last washing step with 1xPBS and then incubated for 10 minutes at room 
temperature. To stop the reaction and get the final color signal, 25µl of a 5% H2SO4 solution was added. 
Subsequently, the samples were measured by means of Tecan Sunrise reader and analyzed. To prepare 
a standard curve for the final calculation, a sample with a known concentration (290ng/ml) was carried. 
2.2.2.2 Measurement of the luciferase activity 
In the luciferase assay, reporter constructs carrying a firefly luciferase gene behind a CMV promotor and 
after this, the sequence which is important to produce virus particles. The luciferase catalyzes a reaction 
in which light is emitted whose intensity is proportional to the amount of produced firefly luciferase. 
This allows conclusion to be drawn about the rate of synthesis of HERV-K virus like particles. For 
infection experiments, cells were incubated for one hour at 37°C with viruses which have the luciferase 
construct. After this step the cells were washed with PBS and cultivated with the standard growth 
medium at 37°C. 48 hours after infection, the cells were lysed with 200µl 1x Passive Lysis Buffer 
according to the manufacturer. 20µl of the lysate were pipetted into a white 96-well luminometer plate 
and the light intensity was measured after a 10 seconds delay with the Berthold Centro LB 960 
luminometer. This device automatically injected 50µl of the firefly luciferase substrate into each well. 
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2.2.2.3 SDS-Polyacrylamide gel electrophoresis (SDS-Page) 
The SDS-Page is a method for separating denatured proteins by size in the electric field (LAEMMLI, 
1970). Sodium dodecyl sulfate (SDS) leads to denaturation of proteins and covers their own charge. 
Thus, all SDS-loaded proteins get a negative charge and, due to their unequal size, migrate in the gel at 
different rates and under the influence of the electric field thus separated. 4% stacking gels and 12% 
running gels (table 16) with a thickness of 1.5mm were used, the concentration of the separation gel 
depending on the size of the proteins to be separated. The smaller the protein to be separated, the 
higher should be the separating gel. The optimum range of rotation of 12% running gels is 72kDa to 
34kDa. The wide-pored, stacking gel preceded by the separating gel accounts for about one quarter of 
the total gel and serves to concentrate the sample at the boundary layer of the two gels. Thus, the 
sample penetrates into the running gel as a very thin band and can be separated in a clearly structured 
manner. The components of the gels are blended together, with ammonium persulfate (APS) and N, N, 
N’, N’-tetramethylethylendiamine (TEMED) catalyzing the crosslinking of the acrylic monomers. Before 
applying the protein samples, they were isolated from fresh cultivated cells with RIPA-buffer for 10 
minutes on ice. After a centrifugation with 15,000 RPM for 10 minutes the protein concentration of the 
supernatant was analyzed by Pierce BCA Protein Assay Kit from Thermo Fisher (proceed as described by 
the manufacturer). Before applying the samples, they treated with the same volume of 6x Laemmli 
sample buffer and 5% β-mercaptoethanol and denatured for 10 minutes at 95°C in a heating block. The 
hydrogen bonds of the tertiary and secondary structures are broken up by the SDS and the disulfide 
bridges are reduced by β-mercaptoethanol. The concentration of the samples and the size standard in 
the stacking gel was carried out at 100V until the running front passed through the boundary layer to 
the running gel. The voltage was increased to 120V to separate the samples until the run front started to 
run out of the gel after about 90 minutes. This was followed by Western Blot analysis as described in the 
next section.  
TABLE 15: Composition of 3 stacking and running gels 
Components 4% Stacking Gel 12% Running Gel 
ddH2O 8.9ml 7.9ml 
30% Acrylamide 2ml 9.6ml 
0.5M Tris pH 6.8 3.75ml 6ml 
10% SDS 150µl 240µl 
10% APS 150µl 240µl 
TEMED 15µl 24µl 
Total Volume 15ml 24ml 
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2.2.2.4 Western Blot analysis 
The size-separated proteins were transferred to a nitrocellulose membrane in the Western Blot and 
subsequently identified and quantified using specific antibodies. First, the tailored membrane with a 
pore of 0.45µm and SDS gel was washed in transfer buffer for at least 20 minutes. After this, the protein 
transfer was done by semi-dry blotting procedure. For this, the gel was placed on the membrane 
between two blotting papers soaked in transfer buffer and blotted for 45 minutes at 15V. Subsequent 
pivoting of the membrane in milk powder buffer overnight blocked non-specific antibody bindings. 
Incubation of the primary antibody (which was diluted in PBS-T) was for one hour at room temperature 
or overnight at 4°C. After washing three times in PBS-T for five minutes each, the membrane was 
incubated with fluorescent labeled secondary antibody, which was also diluted in PBS-T, for one hour at 
room temperature in the dark. After another washing step with PBS-T, the fluorescence signal was 
evaluated on the Odyssey Infrared Imaging System.  
 
2.2.3 Molecular biological methods 
2.2.3.1 Transformation 
The transformation of the plasmids was carried out by means of One Shot™ Top10 chemically 
competent E. coli. The protocol “Chemical transformation procedure” from the manufacturer was used 
for the experiments. Part of the transformation mixture was then plated on LB agar selection plates 
supplemented with ampicillin or kanamycin.  
 
2.2.3.2 Plasmid cloning and isolation 
For the cloning of plasmids “One Shot Top10” were transformed with these, shaken and plated out, as 
already described in the previous section. The next day, the single colonies were transferred to 2ml LB 
medium supplemented with ampicillin or kanamycin and shaken at 37°C and 250rpm for 4-8 hours. This 
2ml day-culture was transferred to 2 2L baffled flask with 250ml LB medium and shaken overnight under 
the same condition. The subsequent plasmid isolation was carried out according to the manufacturer´s 
instructions by means of Plasmid Maxi Kit (25). The DNA was diluted in 200µl distilled water and the 
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2.2.3.3 Glycerol stock 
In order to accelerate the cloning process for commonly used plasmids glycerol stocks were made. 500µl 
of the bacterial solution were taken from the overnight culture before starting the plasmid isolation, 
mixed together with 500µl of 95% glycerol and stored at -80°C. For future plasmids preparations, a 
pipette tip was dipped briefly in the glycerol stock and placed in the 2ml LB medium and shaken at 37°C 
and 250rpm. 
2.2.3.4 DNA quantification 
The DNA quantification was carried out with a NanoDrop1000 according to the manufacturer, at a 
wavelength of 260nm and 280nm. For the absorption measurement of the DNA, 1µl of the eluted DNA 
was used. To make a statement about the purity of the DNA, the coefficient was calculated from the 
optical density at 260nm and 280nm. The highly purified DNA had a barely measurable protein 
concentration, which was reflected in a coefficient of 1.8 to 2.0. 
2.2.3.5 Restriction with endonucleases  
For verification of vectors and for cloning, the DNA was digested with specific bacterial restriction 
endonucleases (table 8). They each recognize one specific palindrome-like sequence within the DNA and 
produce there ends with 5’ overhang. The various type II restriction endonucleases were added to the 
DNA for approximately one hour at 37°C. To analyze the restriction digest were the mixtures are 
checked by DNA agarose gel electrophoresis.  
Approach – Digestion: 1000ng Plasmid 
   2.5µl Endonuclease Buffer 
   1µl Endonuclease 
   add. to 25µl Aqua dest. 
2.2.3.6 DNA agarose gel electrophorese  
DNA agarose gel electrophoresis as a standard method is used to control, identify and purify nucleic 
acids by size and charge. The agarose powder was boiled with 1xTAE buffer to 0.8-1.5% agarose 
solution, depending on the size of the DNA to be separated. For this work, 0.8% agarose gels were used 
and 0.5µg/ml ethidium bromide was added. Ethidium bromide binds to the DNA during separation in 
the electric field, thus allowing visualization under UV light. Before applying the samples, they were 
spiked six times with 6x DNA loading dye and separated at a voltage of 90V in an electric field. The 
status of the sample separations could be tracked by means of Orange-G in the DNA loading dye. By 
carrying a size standard, a sizing and assignment of the fragments was possible. The documentation of 





3.1 Viral entry by transfection of specific receptors 
3.1.1 The effect of the HERV envelope proteins syncytin-1 and syncytin-2 for cell 
fusion 
To carry out the receptor expression experiments, the epithelial cell line HEK293T was used. After 
transfection of the receptors ASCT1 and ASCT2 for syncytin-1 and MFSD2A for syncytin-2, morphological 
changes on the cell line could be observed after 24 hours. Not only a reduction in the number of cells, 
but also a slight clumping of the cells in the monolayer was evident.  
 
           
      A) untransfected HEK293T             B) ASCT1 transfected HEK293T 
           
      C) ASCT2 transfected HEK293T            D) MFSD2A transfected HEK293T 
Figure 8: Differences in the morphology and growth behavior of HEK293T in the monolayer with 
different receptor transfections 
After transfection with different plasmids, some of the cells died and others fused easily to the membrane. The reason for this 
was the formation of receptors for syncytin-1 (B and C). While the untransfected cell line (A) had a cobblestone-like structure, 
no clear cell structure could be detected in the cells with ASCT1 and ASCT2 (red arrows). The cells with the receptor for 






For this entry experiment, pseudotyped HI viruses with a HERV-K (Δc1), VSV-G, syncytin-1 and syncytin-2 
envelope and a luciferase activity were prepared. After transfection with the specific receptors and 
infection with the pseudotyped viruses, the luciferase activity was measured and evaluated in the 
diagrams in figure 8. The untransfected HEK293T cells were considered to 100% and the infection of the 
transfected cells was normalized to these. The left diagram clearly shows that a simultaneous 
transfection with ASCT1 and ASCT2 has reached the highest infection rate for the control syncytin-1. 
Here a 17-fold higher infection could be determined, as if the receptors were transfected individually. 
Also in the right diagram, the syncytin-2 pseudotyped HI virus infected the MFSD2A transfected 
HEK293T cells 8-fold more. The other control infection with the VSV-G viruses showed a constant 
infection rate in every condition. Based on these control infections, it can be said that the receptors 
have no influence on the entry of Δc1 pseudotyped HI viruses into the ASCT1/2 and MFSD2A transfected 
cells. None of the infections with Δc1 shows an increased infection rate, as this is even lower than in the 
untransfected cells.  
 
 
          
Figure 9: Infection of pseudotyped HI viruses of ASCT1/2 and MFSD2A transfected HEK293T cells 
On the left side you can see the infection of ASCT1 and ASCT2 transfected HEK293T cells with HERV-K (Δc1) pseudotyped HI 
viruses. An infection with syncytin-1 pseudotyped viruses of ASCT1 and ASCT2 transfected cells has a 17-fold higher possibility 
to enter the cell, than untransfected cells. The right diagram shows the infection rate of HERV-K (Δc1), syncytin-2 pseudotyped 
HI viruses to MFSD2A transfected HEK293T cells. The values were normalized to the untransfected cell line, which was set to 
100%. The non-functional virus mutants R140C and VSV-mutant, as well as the PBS control (mock), did not show luciferase 















































































To evaluate the data, a western blot was used to check if the receptors were expressed on the cell 
surface. Since the transfected plasmids had a Myc- and Flag-tag, the expression could be detected by 
means of specific antibodies. The blot was evaluated by fluorescence labeled antibodies and Flag was 
shown in green and GAPDH in red. As can be seen GAPDH was detected at about 37kDa and ASCT1/2 at 
55kDa and MFSD2A at about 60kDa. Since the untransfected cells have no Flag-tag, it can be assumed 
that the transfection of the receptors in HEK293T cells was successful. 
 
 
Figure 10: Western Blot of ASCT1/2 and MFSD2A transfected HEK293T cells with Flag and GAPDH 
antibodies 
The Blot shows the expression of GAPDH (red) and the Flag-tag (green) of ASCT1/2 and MFSD2A. The markers on the left and 
right side provide information on the approximate size of the proteins sought from 10kdA to 170kDa. The samples from left to 
right are ASCT1, ASCT2, ASCT1 + ASCT2, MFSD2A and untransfected HEK293T cells. 
 
3.1.2 Transfection of receptor candidates for specific HERV-K (HML-2) entry 
To confirm the exact receptor responsible for HERV-K (HML-2) entry, several receptor candidates were 
transfected into the HEK293T cell line. After infection with HERV-K pseudotyped HIV and various control 
viruses, the luciferase activity was measured and evaluated in the following diagram. The luciferase 
activity shows that none of the receptors used improved the entry of the virus Δc1. Only the HEK293T 
cells with transfected g-protein coupled receptor 56 showed a significant increase in the entry of Δc1 
into the cell. The virus infected the cells with the GPR56 cells without this receptor. Due to the strong 










Figure 11: Luciferase Activity after infection of HEK293T cells with specific receptor candidates 
The diagram shows the luciferase activity of the pseudotyped HI viruses used for the infection. The activity of the viral infection 
of the untransfected cells was set to 100% and the rest was normalized to this. HEK293T cells were transfected with 2 different 
types GPR56, as well as GPR161, CD63, L1CAM, sortilin 1 and neuroligin 1. The non-functional virus mutants R140C and VSV-
mutant, as well as the PBS control (mock), did not show luciferase activity after infection. Due to the biological replicates  a 
standard deviation was determined.  
 
To verify that the receptors were expressed on the cells, lysates of the HEK293T cell line were checked 
by western blot analysis. Due to the different tags expression could be detected with the help of 
suitable antibodies. This revealed that all of the detectable receptors were expressed in the cells. The 
detection of neuroligin 1 was not possible due to the non-specific antibody binding and should possibly 
be repeated. Likewise, L1CAM and BC-GPR56 could not be tested because they did not have a tag and a 
specific antibody was not present. Since the receptor CD63 had an EGFP-tag, it could be detected by 
















































        
     A) FLAG and GAPDH             B) HA and GAPDH 
        
    C) HIS and GAPDH            D) CD63-EGFP 
Figure 12: Proven Methods for analysis of transfected HEK293T cells with Receptor candidates 
The western blots show the expression of GAPDH (red), as well as the FLAG-tag (A – green), HA-tag (B – tag) and HIS-tag (C – 
green) of the special receptors. GAPDH has a size of 37kDa and serves as loading control of all blots. A) GPR56 (77kDa) and 
GPR161 (60kDa) were detected by a FLAG antibody. B) GPR56 had a HA-tag in addition of the FLAG-tag. Also neuroligin 1 (NL1 - 
93kDa) was detected by means of an HA antibody. C) Sortilin 1 (Sort 1 - 92kDa) was detected due to the HIS-tag. The markers 
on the left and right side provide information on the approximate size of the proteins sought from 25kDa to 170kDa. D) The 








3.2 Interaction of specific glycosaminoglycan’s with viral proteins during 
the entry process 
3.2.1 The role of free heparan sulfate for viral binding to the cell surface 
Heparan sulfate is a highly negatively charged extracellular matrix polysaccharide and has a positive 
influence on viral heparan sulfate binding proteins, because the virus can reach the cell membrane for 
entry. Heparan sulfate on the cell membrane are bound with a proteoglycan molecule. For this reason, 
it´s important to know which main influence has the heparan sulfate proteoglycans for the viral entry of 
HERV-K (HML-2). 
To obtain a precise overview of the task of cellular glycosaminoglycan´s various concentrations of free 
heparan sulfates were incubated with HEK293T cells and the viruses used. After incubation of heparan 
sulfate with the virus, the mixture was added to the cells and cultured. Due to the luciferase formation 
of the pseudotyped viruses, it was possible to measure entry into the cell. It turned out that increasing 
the concentration of heparan sulfate does not improve the entry of the virus, but worsens it. The lowest 
infection rate was reached at 400g/ml heparan sulfate, but it has no effect to the VSV-G. The infection 
was reduced from 100% to about 40% due to the heparan sulfate concentration. A slight increase in the 
infection rate of Δc1 of approximately 110% was achieved with the use of 50g/ml. The infection rate was 
normalized to the untreated cells and set to 100%. The functionless virus mutants of Δc1 and VSV-G, as 
well as the PBS control (mock), had no luciferase activity in the cells after infection. 
 
 
Figure 13: Infection rate after heparan sulfate incubation on HEK293T cells 
The diagram shows the entry of the pseudotyped HI viruses Δc1 and VSV-G in HEK293T cells when incubated with 0-400g/ml 
heparan sulfate. The infection rate was measured by viral firefly luciferase activity and normalized to untreated cells and s et to 
100%. The non-functional virus mutants R140C and VSV-mutant, as well as the PBS control (mock), did not show luciferase 














































3.2.2 Enzymatic digestion of heparan sulfate with heparinase I/III 
Further evidence that heparan sulfates are important key players in the entry of HERV-K was the 
enzymatic digestion by heparinase I/III from the surface of SK-Mel28 cells. Heparinases belongs to the 
family of lyases, specifically those carbon-oxygen lyases acting on polysaccharides (Linhardt et al., 1990). 
The cell line was cultured with three different concentrations of heparinase I/III (blend) and infected 
with pseudotyped viruses. The resulting luciferase activity was measured and show that the infection 
rate decreased with increasing heparinase activity. The infection with Δc1 could be reduced by up to 
50%, whereby the VSV-G infection remained almost unaffected. The functionless virus mutants of Δc1 
and VSV-G, as well as the PBS control (mock), had no luciferase activity in the cells after infection. 
 
 
Figure 14: Infection rate after heparinase I/III digestion on Sk-Mel28 cells 
The diagram shows the infection rate in % of Δc1 and VSV-G pseudotyped HIV. The viruses infected Sk-Mel28 cells after 
treatment of 0-10mU/ml heparinase I/III. The infection rate was measured by viral firefly luciferase activity and normalized to 
untreated cells and set to 100%. The non-functional virus mutants R140C and VSV-mutant, as well as the PBS control (mock), 
did not show luciferase activity after infection. Due to the biological replicates a standard deviation was determined. 
 
3.2.3 Chemical inactivation of cell surface sulfation by sodium chlorate 
Sodium chlorate inhibits the synthesis of the sulfate donor PAPS, thereby reducing cell surface sulfation. 
The first experiments were carried out by incubating the Sk-Mel28 cells for one hour with different 
concentrations of sodium chlorate. The diagram in figure 15 shows that sodium chlorate did not affect 
the infection of Δc1 and VSV-G pseudotyped HI viruses. It shows the luciferase activity of the infected 
viruses and was plotted logarithmically. It can be seen that the negative controls R140C, VSV-mut and 
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Figure 15: Viral firefly luciferase activity after incubation for 1h at 37°C with sodium chlorate 
The cell line Sk-Mel28 was incubated for 1 hour at 37°C with 0-100mM sodium chlorate and then infected with pseudotyped 
HIV. The diagram shows the firefly luciferase activity after infection with Δc1, VSV-G, R140C and VSV-Mut, which was displayed 
logarithmically. The non-functional virus mutants R140C and VSV-mutant, as well as the PBS control (mock), did not show 
luciferase activity after infection. Due to the biological replicates a standard deviation was determined. 
 
Due to the fact that the infection rate of Δc1 remained unchanged, the experimental setup was changed 
and the cell line cultured for two passages with three different concentrations of sodium chlorate. By 
this experimental change, the rate of infection of Δc1 could be reduced to 10%, whereas the infection 
with VSV-G remained unchanged at 100%. Thus, it can be said that with increasing sodium chlorate 




































Figure 16: Viral firefly luciferase activity after incubation for 2 passages with sodium chlorate 
 
The cell line Sk-Mel28 was incubated for 2 passages with 0-100mM sodium chlorate and then infected with pseudotyped HIV. 
The diagram shows the firefly luciferase activity after infection with Δc1 and VSV-G, which was normalized to untreated cells 
and set to 100%. The non-functional virus mutants R140C and VSV-mutant, as well as the PBS control (mock), did not show 
luciferase activity after infection. Due to the biological replicates a standard deviation was determined. 
 
To verify the expression profile of heparan sulfates, various western blots were prepared. One antibody 
was used which generally detects heparan sulfates and another antibody detects syndecan-1.  
Syndecan-1 is a cell surface heparan sulfate proteoglycan and functions as an integral membrane 
protein, which is important for disease pathogenesis. On the one hand, the left blot shows that the 
GAPDH expression of the Sk-Mel28 cell line remained the same at 37kDa and thus the loading control 
was successful, as the same protein concentration was used for the blot. Based on the green bands at 
32kDa syndecan-1 expression could be detected. It could be seen that syndecan-1 concentration 
decreased with increasing sodium chlorate concentration. In the right blot, an antibody was used for all 
heparan sulfates in general. Here, at 32kDa the decreasing syndecan-1 expression was best seen by the 
green bars, whereas the GAPDH concentration (red bars at 37kDa) remained the same. The cell line 
Colo205 should server as a positive control, as they contain a high amount of syndecan-1 (figure 22B). 















































        
             A) Syndecan-1                B) Heparan Sulfate 
Figure 17: Western Blot analysis of HSPG´s after sodium chlorate cultivation 
The left blot (A) shows the detection of GAPDH (red) at 37kDa and syndecan-1 (green) at 32kDa. The right blot (B) shows the 
expression of GAPDH (red) at 37kDa and various heparan sulfate proteoglycans (green). The HSPG Syndecan-1 at 32kDa on the 
right blot was particularly good to detect. For analysis, lysates of Sk-Mel28 cultured with different concentrations of sodium 
chlorate were used. Colo205 should serve as a positive control for syndecan-1. However, since the control GAPDH is only 
slightly visible, the detection of syndecan-1 is difficult. The markers on the left and right side provide information on the 
approximate size of the proteins sought from 10kDa to 170kDa. 
 
Due to the microscopically recognizable changes in the proliferation rate of the cells due to the different 
concentrations of sodium chlorate, a growth curve was created. For this, the cells were cultured for 2 
weeks with sodium chlorate and counted daily. After 2 days, the cells adapted to the environment and 
have gone into the exponential phase. The maximum cell division that occurred at this stage ended after 
about 9 days, after which the cells were in the plateau phase. In this section, the detaching cells and 






Figure 18: Growth Curve for Sk-Mel28 cultured with and without sodium chlorate 
The cell line Sk-Mel28 was cultured in 6-well plates without, with 25mM, 50mM and 100mM sodium chlorate and a well 
counted daily. Every two days, a change of medium with fresh sodium chlorate was carried out. The cells per cm² were applied 
logarithmically. 
 
In table 17 it can be seen that the population doubling time (PDT) of the Sk-Mel28 cell line with 100mM 
sodium chlorate is 5.5 times higher than that of the remaining cells. The cells without sodium chlorate 
had a PDT of 29 hours, with a culturing with 25mM a PDT of 34 hours and at 50mM sodium chlorate of 
33.5 hours was determined. In contrast, culturing with 100mM indicated that the PDT increased to 166 
hours.  
TABLE 16: Population doubling time of Sk-Mel28 after sodium chlorate cultivation 
Conditions PDT in hours 
Sk-Mel28 with 0 mM NaClO3 29.1 
Sk-Mel28 with 25 mM NaClO3 34.3 
Sk-Mel28 with 50 mM NaClO3 33.5 
Sk-Mel28 with 100 mM NaClO3 166.4 
 
3.2.4 Overexpression of syndecan-1 on the cell surface of HEK293T 
To evaluate that syndecan-1 is an important factor for HERV-K entry, several cell lines were 
overexpressed with this protein. For this, E. coli were transformed with the SDC1 plasmid and selected 
with ampicillin. After the reproduction of the cells and isolation of the plasmids by the Quiagen Maxi Kit, 
the plasmid was cut with NotI and visualized by using gel electrophoresis and ethidium bromide. The gel 
pattern showed the expected sizes after digestion (+) at around 4700 and 2500 base pairs and thus 




















Figure 19: Gel electrophoresis after enzymatic digestion of syndecan-1 plasmid 
The plasmid SDC1 was digested by the enzyme NotI for one hour at 37°C and applied to the gel (+). 
The control was the undigested plasmid, which is marked with (-). The gel was running for 1 hour at 
90V and the marker on the right side shows the size of the bands from 75 to 20,000 bases. 
 
 
After infection with HERV-K pseudotyped HIV and various control viruses, the 
luciferase activity was measured and evaluated in the following diagram. Due to 
the luciferase formation of the pseudotyped viruses, it is possible to measure 
entry into the cell. The diagrams in the figures 20 and 21 shows that a syndecan-1 
overexpression did not affect the infection of Δc1 and VSV-G pseudotyped HIV. 
The cell line HCT116 was used because the cells express no syndecan-1 (figure 
22B) and the entry of Δc1 is difficult. However, expression of syndecan-1 in HCT116 did not result in 
increased Δc1 entry into the cell. The diagrams show the luciferase activity of the infected viruses and 
was plotted logarithmically. It can be seen that the negative controls R140C, VSV-Mut and mock had no 
luciferase activity, whereas VSV-G had a constant infectivity.  
 
 
Figure 20: Viral infection of syndecan-1 overexpressed HEK293T cells 
The cell line HEK293T was transfected with syndecan-1 and then infected with pseudotyped HIV. The diagram shows the firefly 
luciferase activity after infection with Δc1, VSV-G, R140C and VSV-Mut, which was displayed logarithmically. The non-functional 
virus mutants R140C and VSV-mutant, as well as the PBS control (mock), did not show luciferase activity after infection. Due to 


































Figure 21: Viral infection of syndecan-1 overexpressed HCT116 cells 
The cell line HCT116 was transfected with syndecan-1 and then infected with pseudotyped HIV. The diagram shows the firefly 
luciferase activity after infection with Δc1, VSV-G, R140C and VSV-Mut, which was displayed logarithmically. The non-functional 
virus mutants R140C and VSV-mutant, as well as the PBS control (mock), did not show luciferase activity after infection. Due to 
the biological replicates a standard deviation was determined. 
 
To assess a successful transfection with syndecan-1, a western blot (figure 22A) with the prepared cell 
lysates was performed. The specific antibody for syndecan-1 detected the syndecan-1 core at 77kDa 
(green) for both transfected cell lines. GAPDH (red) was detected in all samples with equal intensity at 
37kDa. To compare the transcript intensity, z-scores for the cell lines Colo205 and HCT116 of HSPG2 and 
syndecan-1 were determined (figure 22B). Based on these data, HCT116 was used for this experiment.  
 
         
      A) Western Blot SDC1        B) Z-Scores  
Figure 22: Western Blot analysis of syndecan-1 transfected cells and specific Z-scores 
A) The blot shows the detection of GAPDH (red) at 37kDa and the core of syndecan-1 (green) at 77kDa. For analysis, lysates of 
transfected HEK293T and HCT116 were used. The markers on the left and right side provide information on the approximate 
size of the proteins sought from 10kDa to 170kDa. B) The diagram shows the transcript intensity of Colo205 and HCT of HSPG2 


























































3.2.5 Reduction of syndecan-1 expression by specific shRNA´s 
In order to analyze how the infection rate of pseudotyped HIV changes when the expression of 
syndecan-1 is reduced, the cells were incubated with special shRNA´s. A short hairpin RNA is an artificial 
RNA molecule with a tight hairpin turn. The expression of shRNA in the cell lines was done by the 
transfection of specific plasmids. It has the advantage, that this have a relatively low rate of degradation 
and turnover. In addition to the shRNA, the genetic information for puromycin resistance is also on the 
plasmid. Due to this fact, the successfully infected cells could be selected by puromycin. For a precise 
concentration, different values of 0-5µg/ml puromycin were added to untransfected Sk-Mel28 and 
HEK293T and cultured for several days. In figure 23 it could be seen that all HEK293T cells died at 
1.5µg/ml and all Sk-Mel28 at 1µg/ml. For this reason, the transfected cells were cultured with these 
puromycin concentrations to obtain a stable transfected cell line.  
 
 
Figure 23: Puromycin kill curve for Sk-Mel28 and HEK293T 
The diagram shows the minimal puromycin concentration at which untransfected HEK293T and Sk-Mel cells were no longer 
viable. Vitality was expressed in percentage of surviving cells. At 0.5µg/ml, a reduction in cell vitality was already evident. Cell 
death from Sk-Mel28 could be detected at 1µg/ml and from HEK293T at 1.5µg/ml. 
 
 
After infection with HERV-K pseudotyped HIV and various control viruses, the luciferase activity was 
measured and evaluated in the following diagram. Due to the luciferase formation of the pseudotyped 
viruses, it is possible to measure entry into the cell. The diagram in figure 24 shows that a syndecan-1 
reduction effect the infection rate of Δc1 pseudotyped HIV. It was used for the infection 1µg and 2µg of 
plasmids because prior the experiment, it was not clear which would be the optimal concentration for 
shRNA production. After evaluation of luciferase activity, it could be seen that a transfection of 2µg 































The entry of HERV-K could be reduced by 70% in HEK293T and by 40% in Sk-Mel28. The infection rate 
was normalized to the untreated cells and set to 100%. The functionless virus mutants of Δc1 and VSV-
G, as well as the PBS control (mock), had no luciferase activity in the cells after infection. 
 
 
            
Figure 24: Viral infection of HEK293T and Sk-Mel28 after syndecan-1 reduction by shRNA 
The cell line HEK293T (left) and Sk-Mel28 (right) was transfected with syndecan-1 shRNA (by a plasmid) and then infected with 
pseudotyped HIV. The diagram shows the firefly luciferase activity after infection with Δc1 and VSV-G, which was normalized to 
untreated cells and set to 100%. The non-functional virus mutants R140C and VSV-mutant, as well as the PBS control (mock), 
did not show luciferase activity after infection. Due to the biological replicates a standard deviation was determined. 
 
 
To verify the expression profile of syndecan-1 in shRNA transfected Sk-Mel28 cells, a western blot was 
performed with a specific syndecan-1 antibody. For this experiment the cell lysates from no transfected 
and with 1µg and 2µg plasmid transfected cells were used. The blot shows that the GAPDH expression of 
the Sk-Mel28 cell line remained the same in every sample at 37kDa. Based on the green bands at 32kDa 
syndecan-1 expression could be detected. It could be slightly seen that after transfection the syndecan-1 
concentration decreased with increasing shRNA plasmid concentration. In HEK293T cells it was not 






















































































Figure 25: Western Blot analysis of syndecan-1 shRNA transfected Sk-Mel28 cells 
The Blot shows the expression of GAPDH (red) and syndecan-1 (green) of shRNA transfected Sk-Mel28 cells. The shRNA inhibits 
the mRNA of syndecan-1 and thus prevents protein expression. The markers on the left and right side provide information on 
the approximate size of the proteins sought from 10kdA to 170kDa. The samples from left to right are untransfected cells and 
then transfected cells with 1µg and 2µg shRNA plasmids. No syndecan-1 could be detected in HEK293T cells. For this reason, 





























4.1 The importance of specific receptors for the entry of HERV-K  
(HML-2) into the cell 
The human genome consists of 8% retroviral elements with terminal LTRs, 4.7% of which are human 
endogenous retroviruses (HERVs) (Bannert and Kurth, 2004; Beimforde et al., 2008; Lander et al., 2001). 
HERVs were also once exogenous retroviruses that infected human endocrine cells, endogenized and 
multiply integrated into the genome by reinfection and retrotransposition (Gifford and Tristem, 2003). 
The replication of retroviruses begins by infection of the host cell. The virus, mediated by its 
glycosylated cot proteins, attaches to specific receptors of the cell. It leads to the fusion of the virus 
envelope with the plasma membrane or to the endocytosis of the entire viral particle. For this reason, 
one of the two main tasks in this work was to find the specific receptor for HERV-K entry into the cell. 
For this purpose, the receptors of the syncytins and various other receptor candidates were considered, 
which were analyzed in many previous work in the working group.  
The env genes of HERV-W and HERV-FRD, better known as syncytin-1 and syncytin-2, influence placental 
development (Bannert et al., 2018). The human syncytin-1 is a cell-cell fusion protein and is involved in 
the fusion of the cytotrophoplasts cells and thus leads to the formation of the polynuclear 
syncytiotrophoblast (Blond et al., 1999; Blond et al., 2000; Mi et al., 2000; Pötgens et al., 2004). The 
syncytin-1 receptor is the sodium dependent amino acid transporter 1 (ASCT1 or SLC1A4) and 2 (ASCT2 
or SLC1A5). Syncytin-2 carries through its immunosuppressive properties of mother-to-child tolerance 
during pregnancy (Malassiné et al., 2007). The syncytin-2 receptor is the sodium-dependent 
lysphosphatidylcholin symporter 1 (MFSD2A), which plays an essential role for blood-brain barrier 
formation and function and acts as a receptor in placenta. Recent studies have pointed to the 
expression of the HERV-K envelope protein in cells of the placental cytotrophoblast, but not in the 
syncytiotrophoblast. Therefore, it can be assumed that syncytin receptors also play a significant role in 
the entry of HERV-K. 
For this experiment, the cell line HEK293T was transfected with the receptors ASCT1, ASCT2 and 
MFSD2A. Already a microscopic control of the cells after 24 hours showed that the cells started to clump 
together after transfection. Due to the property of cell-cell fusion, which can be seen in figure 8, one can 
assume that the transfection was successful. The western blot also showed a successful transfection 
efficiency, since the Flag-tag of the transfected receptors could be detected in all samples, except of the 
untransfected cells. Due to this fact, the infection experiments could be carried out. For this purpose, 




the firefly luciferase assay showed that transfection of the specific receptors resulted in increased 
syncytin-1/2 virus entry into the cells. This and the consistent infection rate of VSV-G indicates that 
infection with HERV-K pseudotyped HIV (Δc1) can be successfully evaluated. The viral entry experiments 
with Δc1 did not result in a higher infection rate after transfection of syncytin receptors. This was due to 
the fact that none of the samples had a higher infection than untransfected HEK293T cells. Due to this 
fact, it could be assumed that the receptors ASCT1, ASCT2 and MFSD2A were not the specific receptors 
for the entry of HERV-K (HML-2).  
This was the reason that new receptor candidates had to be used for further entry experiments. 
Previous work by N. Bannert and A. Richter compared different gene profiles of successfully infected 
cells with HERV-K and thus identified potential receptors that might be specifically involved in the onset 
of the virus. These receptors were the G protein-coupled receptors 56 and 161, the cell surface receptor 
CD63, the neural cell adhesion molecule L1CAM, the Golgi sorting receptor sortilin-1, and the cell 
surface protein neuroligin-1. The plasmids of these receptors were brought into the cells by means of 
PEI transfection and checked for successful expression by western blot and fluorescence. The images in 
figure 12 showed that GPR56, GPR161, Sort1 and CD63 could be successfully detected. Due to the non-
specific bands in Neuroligin-1 and the fact that L1CAM and BC-GPR56 (another plasmid for GPR56) had 
no protein tag, expression could not be detected here. The infection experiments with the pseudotyped 
HIV showed that VSV-G had a consistent infection in all samples. Slight differences compared to the 
untransfected cells were seen in the infection with Δc1. However, especially transfection with GPR56 
increased the infection rate 3-fold to the untransfected cells. This suggests that GPR56 may play an 
essential role in the specific entry of HERV-K. The adhesion G protein-coupled receptor G1 (GPR56) is 
involved in cell adhesion and probably in cell-cell interactions. Collagen III is a ligand of GPR56 in the 
developing brain and the receptor binds transglutaminase 2 (TG2) to suppress tumor metastasis (Luo et 
al., 2012).  
 
4.2 Heparan sulfate proteoglycans on the cell surface as the main 
component for the adhesion of HERV-K (HML-2) 
HSPG´s are a group of proteins that have at least one covalently linked heparan sulfate (HS) side chain. 
This side chains bind a variety of growth factors, extracellular matrix factors and other proteins, 
indicating that HS side chains bind to cell adhesion or regulation of cell division activity (Carey, 1997). In 
addition, it is known that various pathogens interact with the heparan sulfate proteoglycans, because 
the HS has a positive influence on viral heparan sulfate binding proteins. Often, binding of a viral protein 




required for viral entry into the cell and the initiation of infection. As many microorganisms, HIV-1 also 
interacts with heparan sulfates, because the gp120 protein which is important for the first contact with 
the CD4 receptor, interacts with a variety of HS (Connell and Lortat-Jacob, 2013). Zhang et al. described 
in their paper that the Coxsackievirus A16 uses surface HSPGs as a binding receptor. Coxsackievirus A16 
(CVA16) is one of the major pathogens responsible for hand, foot and mouth disease, which affects 
more than two million children in the Asian-Pacific region annually (Zhang et al., 2017). This and many 
other experiments were the motivation to analyze the role of heparan sulfate proteoglycans in the entry 
of human endogenous retroviruses into the cell. 
One of the main experiments was the interaction of free heparan sulfate with the cell surface and the 
viruses used for the infection. The diagram in the figure 13 showed that the infection rate of Δc1 
decreased with increasing heparan sulfate concentration. The reduction of the infection down to 40% 
could be due to the fact that the HS-binding proteins on the virus surface was saturated with free 
heparan sulfate and thus the virus no longer had the possibility to bind to the cell surface. The HS-
binding proteins are normally responsible for allowing the virus to reach and adhere the cell. However, 
this became impossible with increasing concentration of free HS. Furthermore, it is possible that 
heparan sulfate interacts with the potential receptor GPR56 because not only collagen III and TG2, but 
also heparin and heparan sulfate interact with the adhesion protein. Hence, it is possible that heparin 
and heparan sulfate act as a suppressor (antagonist) of GPR56 receptor function, in part, by inhibiting 
GPR56 receptor shedding, thereby trapping and masking the tethered Stachel peptide agonist and 
preventing the activation of the signaling pathways (Chiang et al., 2016). These two facts could be 
responsible for the reduction of the infection rate. In many papers, heparan sulfate is described as an 
attachment factor for a wide variety of viruses. Zhang et al. used in his work soluble heparin to 
investigate the role of heparan sulfate-specific glycosaminoglycan’s in CVA16 infections. Heparan sulfate 
is structurally related to heparin, only it has less N- and O-sulfate residues and more N-acetyl groups. 
They found, that concentrations of more than 1.56mg/ml heparin could inhibit the cellular attachment 
of CVA16.  
An enzymatic digestion of heparan sulfate with heparinase I and III also reduced the infection rate of 
HERV-K (HML-2) by up to 50%. Heparinases belongs to the family of lyases, specifically those carbon-
oxygen lyases acting on polysaccharides. The enzyme cleaves the glycosidic linkage between 
hexosamines and uronic acids and are known to cleave heparan sulfates selectively, via an elimination 
mechanism. Heparinase I cleaves highly sulfated heparan sulfate chains and heparinase III less sulfated 
chains. In combination the enzyme can produce a near complete depolymerization of polysaccharide 
chains to disaccharides (Linhardt et al., 1990). The enzymatic digestion with a maximum of 10mU/ml 




longer present. Because of this, HERV-K was unable to bind to the cell surface and infect the cells at full 
rate. Plochmann et al. showed that heparan sulfate is an attachment factor for foamy viruses. Enzymatic 
digestion of heparan sulfate on HT1080 cells diminished permissivity for prototype foamy virus entry by 
a factor of at least 500 (Plochmann et al., 2012). Nasimuzzaman and Persons showed that 
concentrations of 4mU/ml heparinase III in NIH3T3 cells could reduce the infection rate of FV up to 10%. 
The analysis was not carried out as in the experiments described here by means of luciferase, but a 
formed GFP signal after successful infection was determined by means of FACS analyzes (Nasimuzzaman 
and Persons, 2012).  
Not only the enzymatic digestion but also the chemical inactivation of cell surface led to the reduction of 
the HERV-K infection rate. Sodium chlorate inhibits the synthesis of the sulfate donor PAPS, thereby 
reducing cell surface sulfation. The sulfation is the major biosynthetic modification of 
glycosaminoglycan’s and the unique and complex sulfation patterns enable them to bind specifically to 
many biomolecules and regulate diverse biological processes (Funderburgh, 2000; Mikami and 
Kitagawa, 2013; Perrimon and Bernfield, 2000). After incubation with sodium chlorate for 1 hour at 37°C 
did not give the expected result, the experiment was repeated after the cells were cultured for several 
days with sodium chlorate. The diagram in figure 16 shows that a high sodium chlorate concentration 
reduces the infection rate of HERV-K. A concentration of 100mM reduced the infection by up to 90% 
compared to 0mM sodium chlorate. However, at this concentration, a microscopic change in cell 
morphology was evident, producing a growth curve. The growth curve in figure 18 shows strong 
proliferation changes of the Sk-Mel28 cell line with 100mM sodium chlorate. Here, the population 
doubling time increased by 5.5-fold compared to 0mM, 25mM and 50mM sodium chlorate. Based on 
this fact, it can be said that the maximum concentration of sodium chlorate to be used was 50mM and 
thus the infection rate of HERV-K could be reduced to 30%. This is the evidence that the sulfation 
pattern of the glycosaminoglycan’s on the cell surface is important for the attachment of the virus. The 
reduction in sulfation was detected by western blot analysis and confirms the statement that an 
increasing concentration of sodium chlorate the sulfation and thus the infection rate decreased. Sodium 
chlorate inhibited the sulfation of HS and thus eliminated the epitope recognized by the antibody.  
Therefore, sodium chlorate-treated cells showed reduction in HS expression compared with untreated 
control cells. Also in the paper by Nasimuzzaman and Persons, sodium chlorate was used to prevent the 
sulfation of HS. It was found, that even a concentration of 25mM reduced the entry of FV in A549 cells 
by up to 95%.  
Another experiment was a HERV-K infection with overexpressed syndecan-1 in HEK293T and HCT116 
cells.  Syndecan-1 is a transmembrane (type I) heparan sulfate proteoglycan and is a member of the 




syndecan receptors are required for internalization of the HIV-1 tat protein (Zhou et al., 2008). The 
syndecan-1 protein functions as an integral membrane protein and participates in cell proliferation, cell 
migration and cell-matrix interactions via its receptor for extracellular matrix proteins. After transfection 
with the specific plasmids for syndecan-1 expression, the cells were infected with various pseudotyped 
HIV. The detection of firefly luciferase in the cells showed that despite overexpression of syndecan-1, an 
increased HERV-K entry into HEK293T cells did not occur. Also in HCT116 cells, which have only a low 
infection rate with HERV-K, an overexpression could not achieve the expected success. Thus, it can be 
said that a greater amount of syndecan-1 proteins on the cell surface did not result in an increased 
HERV-K entry in the cells. To check the transfection efficiency syndecan-1 was detected by western blot. 
It could be seen that after transfection the proteins in the cells were increasingly expressed, since the 
core protein is recognizable at 77kDa.  
Since an overexpression of syndecan-1 did not result in increased HERV-K entry into the cells, the 
expression was reduced by specific shRNAs. A short hairpin RNA is an artificial RNA molecule with a tight 
hairpin turn. The expression of shRNA in the cell lines was done by the transfection of specific plasmids. 
The reduction of syndecan-1 by transfection of 1µg and 2µg plasmid in HEK293T and Sk-Mel28 cells 
reduced the infection rate of HERV-K. In HEK293T the infection could be reduced up to 30% with 2µg 
plasmid. This suggests that the HS-binding protein of the virus had only a small ability to adhere to the 
cells and penetrate. The detection of syndecan-1 by western blot showed that expression decreased 
with increasing plasmid transfection. Therefore, it could be assumed that the reduction in the infection 
rate was due to the inhibition of syndecan-1 expression. Shi et al. described that syndecan-1 is an 
important receptor for the attachment of hepatitis C virus to the cell surface of hepatocytes. Hepatitis C 
virus (HCV) is a common cause of chronic liver diseases such as hepatitis, cirrhosis, and liver cancer. It is 
an enveloped RNA virus containing a single positive-sense RNA genome that encodes a polyprotein 
precursor of 3,000 amino acids (Choo et al., 1989). The knockdown of SDC1 expression by small 
interfering RNA (siRNA)-induced gene silence resulted in a significant reduction of HCV attachment to 
Huh-7.5 cells and stem cell-differentiated human hepatocytes (Shi et al., 2013).  
Nasimuzzaman and Persons described in their work that syndecan-1 has an important role in the 
infection with the foamy virus. Raji cells, which lack HS and were largely resistant to FV, were rendered 
more permissive through ectopic expression of syndecan-1, which contains HS. In contrast, mutant 
syndecan-1-expressing cells were largely resistant to FV. There findings indicate that cellular HS is a 
receptor for FV. Also two mutant CHO cell lines lacking cell surface HS were largely resistant to FV 
attachment and transduction. They described in their study, that they have found that cell membrane-
associated HS serves as a receptor for FV based on the following evidence: (i) HS-deficient cells are less 




removal of the sulfate group from cells greatly reduces FV permissiveness, and (iii) induction of HS 
expression makes cells more permissive to FV (Nasimuzzaman and Persons, 2012). This was also 
demonstrated in these carried experiments for HERV-K entry. Only the expression of syndecan-1 in 
different cells could not increase the infection.    
The research article „Reconstruction of the cell entry pathway of an extinct virus” was published in 
august 2018 and described a few parts from the experiments in this thesis. They published this paper 
during my work and confirmed the results of the viral entry of HERV-K (HML-2) in connection with the 
use of free heparan sulfate and the chemical inactivation of the cell sulfation. The major conclusion of 
this study was that heparan sulfate is a direct HERV-K attachment factor. They create a model (figure 26) 
for the entry of HERV-K, in which is shown the viral binding to heparan sulfate, the endocytosis in a 
dynamin-dependent, clathrin independent manner and an acidification of the endosome which is 
leading to membrane fusion and infection.  
 
 
Figure 26: Model of HERV-K entry 
1. HERV-K binds to HSPGs on the cell surface. 2. Endocytosis in a dynamin-dependent and clathrin-independent manner. 3. 
Releasing of the viral core into the cytoplasm by acidification of the endosome (Robinson-McCarthy et al., 2018). 
 
In contrast to this work, the experiments in this thesis showed that syndecan-1 in particular has an 
important role in viral attachment. Furthermore, it could be shown that not only the HSPGs can be 
responsible for the viral entry, since it was not possible to reduce the infection rate of HERV-K to zero by 
reducing the heparan sulfates. The receptor experiments proved that the G protein-coupled receptor 56 
may be a specific factor for HERV-K entry. Thus, it could be said that the heparan sulfates such as 
syndecan-1 are responsible for attachment to the cells and GPR56 for endocytosis. To be able to make a 





In this work, it has been possible to show that heparan sulfate proteoglycans have an important role in 
the onset of HERV-K (HML-2). To further investigate the interaction between heparan sulfate and virus, 
it has been demonstrated that the heparan sulfate binding proteins on the viral envelope are 
responsible for contact with the cell surface. For example, binding experiments using surface plasmon 
resonance (SPR) analyzes could be performed. Here, heparan sulfates are coated on the specific prism 
and the virus is added after certain analytic steps. Based in the analysis of the date, it could be seen 
whether HERV-K binds specifically to the heparan sulfates. You could also use special heparan sulfates 
such as syndecan-1 and syndecan-2. As already shown, syndecan-1 is essential at viral entry because 
reduction of syndecan-1 molecules on the cell surface resulted in a reduction in the rate of infection. 
However, it is still important to see how the surface profile of the cells is built up. A pure western blot 
analysis is not enough, because you cannot be sure of the protein has reached its true destination. It is 
indistinguishable whether the receptor is on the cell surface or in the cytoplasm. For this reason, further 
work on this topic should explore the cell surface by using FACS analysis. It can be seen exactly whether 
the use of the shRNA for syndecan-1 could change the surface concentration. Furthermore, it can be 
seen whether overexpression with syndecan-1 led to the desired success on the surface of the cells. As 
can be seen in the western blot, the core protein of syndecan-1 was detected at 77kDa only in 
transfection with the specific plasmid. In contrast, the naturally occurring syndecan-1 became visible in 
Sk-Mel28 at a size of 32kDa. In order to determine the cause, FACS analyzes are essential.  
In order to establish a connection between the G protein-coupled receptor 56 and the heparan sulfate 
proteoglycans, it is particularly important to see whether both proteins interact with each other. For this 
purpose, one can analyze whether heparan sulfate actually acts as an antagonist for the receptor and 
inhibits the signal cascade. In this case, it is necessary to know which reactions an activation of the 
receptor is triggered intracellularly and can follow. Only then can one determine and check exact 
interactions. However, this information should be easily ascertainable through special reading. In a 
potential interaction of HS with the GPR56, one could still draw conclusions about an interaction with 
HEERV-K. One approach would be to reduce the receptor expression via shRNA or to block certain 
signaling pathways within the cell. This allows one to see if the receptor is responsible for the entry of 
HERV-K (HML-2). 
To analyze which of the different receptors is responsible for the entry of HERV-K should have the 
highest priority, as this could be essential for a possible drug development. At the present time, 
however, it can be said that various heparan sulfates and GPR56 could play a crucial role in the entry of 
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